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Thesis Abstract
Cervical cancer is a public health problem particularly in developing countries 
where incidence of cervical cancer remains high, either due to a lack of screening 
or poorly organised screening programmes. Cytology based cervical screening is 
only beneficial if women with abnormal Papanicolaou (Pap) smears are 
appropriately investigated. Colposcopy attendance following an abnormal Pap 
smear is a major problem in South Africa. The aim of this study was to explore 
barriers and facilitators to colposcopy attendance following an abnormal Pap 
smear result. 
A qualitative study was conducted at a public sector tertiary hospital colposcopy 
service and two primary health care clinics in Cape Town, South Africa. Data 
collection included 32 semi-structured interviews: 12 face-to-face interviews with 
colposcopy clinic attendees, 12 telephonic interviews with colposcopy clinic non-
attendees and 8 face-to-face interviews with health care providers. Client 
interviews explored barriers and facilitators to colposcopy attendance; knowledge 
and experiences of Pap smears, cervical cancer and the colposcopy procedure; 
scheduling of colposcopy appointments; provider communication; reasons for 
non-attendance; and community support and beliefs. Provider interviews explored 
barriers and facilitators to colposcopy attendance from a provider’s perspective, 
the colposcopy referral process, and provider challenges in the provision of Pap 
smear or colposcopy services. 
Results from this study highlighted that the main barriers to colposcopy 
attendance were: poor levels of knowledge of the importance of a Pap smear and 
the colposcopy procedure; a lack of awareness of cervical cancer as a disease; a 
fear of cancer; the asymptomatic nature of the disease; and transport costs. Health 
system factors that impacted negatively on colposcopy clinic attendance included: 
the inadequate feedback of Pap smear results – clients were not informed of Pap 
smear results or colposcopy appointments and therefore did not attend; a 
disjointed system of colposcopy scheduling; and staff shortages which resulted in 
less time for client tracking. Factors which promoted colposcopy attendance 
included experiencing symptoms; a family history of cancer due to the experience 
Vwith death; colposcopy services situated closer to clients; and social support 
received from family members. 
Addressing these barriers requires promoting client knowledge with educational 
materials and improving provider communication with clients. In addition, 
establishing colposcopy services closer to clients and standardising the system of 
colposcopy scheduling can improve colposcopy adherence.
This thesis is presented in 3 parts
Part A: The proposal for a qualitative study exploring barriers and facilitators to 
colposcopy attendance following an abnormal Pap smear result. The proposal was 
submitted to the University of Cape Town Health Sciences Human Research 
Ethics Committee for ethics approval. 
Part B: Includes a review of the literature evaluating cervical screening 
programmes, and barriers and facilitators to colposcopy attendance, in developed 
and developing countries. Gaps in the literature include qualitative research 
exploring reasons for poor colposcopy attendance in South Africa. Little is also 
known about women’s knowledge and experiences of an abnormal Pap smear 
result, cervical cancer and   the colposcopy procedure in a South African setting. 
Part C – Includes a journal article, prepared to meet requirements of the BMC 
Public Health journal. The article reports on barriers and facilitators to colposcopy 
attendance following an abnormal Pap smear result from client and provider 
perspectives.
Referencing Style: The BMC Public Health referencing style has been used 
throughout the dissertation (Appendix 11)
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1PART A: PROJECT PROPOSAL
2PART A: PROJECT PROPOSAL
Barriers and Facilitators to Colposcopy Attendance Following an 
Abnormal Pap Smear Result: Patient and Provider Perspectives
1. Introduction
Cervical cancer is a major public health concern affecting women worldwide. It is 
the second most common cancer among women globally [1]. In 2012, worldwide 
estimates were 527 624 new cervical cancer cases and 265 653 deaths [2]. More 
than 85% of cases occurred in developing countries [3]. A decline in cervical 
cancer incidence and mortality has been achieved in developed countries, due to 
the successful implementation of organised cytology-based screening programmes 
[4], with high screening coverage and treatment of precancerous lesions [5]. In 
contrast, developing countries either have no or poorly organised screening 
programmes [6] with poor follow-up and feedback mechanisms, inadequate 
referral systems and under-treatment of abnormal Papanicolaou (Pap) smears [7].
A successful cytology-based screening programme is dependent on women with 
abnormal Pap smears attending follow-up assessments [8]. Abnormal smears are 
classified by the Bethesda system as: a smear having atypical squamous cells of 
undetermined significance (ASCUS); high grade squamous intraepithelial lesions 
(HSIL); low grade squamous intraepithelial lesions (LSIL) or atypical squamous 
cells, but cannot exclude HSIL (ASC-H) [9]. The ultimate goal of cervical 
screening, which is the prevention of cervical cancer, is only beneficial if women 
with abnormal smears are appropriately investigated and treated [10]. If women 
with abnormal Pap smears do not attend follow-up sessions, this will result in a 
decrease in screening effectiveness, reduce the efficiency of health care resources, 
and increase programme costs [11].
In South Africa, cervical cancer is the second most frequent cancer among women 
[1]. It is estimated that 5743 new cases and 3027 deaths occurred in 2008, with an 
age standardised incidence rate (ASIR) of 26.6 per 100 000 women [12]. 
Incidence and mortality from cervical cancer is projected to increase in South 
3Africa by more than 21% and 27% respectively by 2025 if current trends continue
[1].
A National Cervical Cancer Screening Policy was introduced in South Africa in 
2000, stating that women between the ages of 30- 60 years are entitled to three 
free Pap smears in their lifetime ten years apart [13]. The objective of the policy is 
to decrease the number of new cases of cervical cancer by identifying and treating 
early stages of the disease [13]. If well implemented, the policy has the potential 
to reduce cervical cancer incident cases by 67% over a ten year period, assuming 
that a high coverage is attained [14]. 
Once women have been screened with the Pap smear test those with HSIL, 
persistent LSIL or ASCUS are referred for colposcopy [15]. Colposcopy is a 
specialised procedure using a colposcope with a strong light to examine the 
uterine cervix for cervical abnormalities and allows a biopsy to be obtained for a 
histological diagnosis [16]. Colposcopy services in South Africa are primarily 
offered in urban areas, at tertiary and a few secondary hospitals, and performed by 
a gynaecologist [17].
South Africa faces many challenges in the implementation of an effective 
cytology-based screening programme [7]. Some of these challenges include: 
human resource shortages, resource constraints, poorly functioning health systems 
[18], competing health priorities, and lack of access to health services, particularly 
by women with a low socioeconomic status (SES) living in rural or urban areas 
[5]. A key challenge is poor colposcopy attendance following an abnormal Pap 
smear [7]. 
Loss to follow-up (LTFU), non-adherence, and default to follow-up care have 
been used interchangeably in the literature. Non-adherence has generally been 
classified as failure to present at a follow-up assessment or treatment following an 
abnormal Pap smear result within a specified time frame [19, 20]. Time frames 
vary between studies. The National Breast and Cervical Cancer Early Detection 
Programme in the United States (US) has defined adherence as completion of 
diagnostic tests within 60 days of the abnormal Pap smear result [21], whereas in 
a systematic review from the US, the reviewed research defined follow-up care 
4ranging from four to six weeks to within 18 months or by the number of follow-up 
appointments attended [19].
A study in Gauteng reported LTFU of over 50% among women who were 
referred to colposcopy with high grade lesions and invasive cancer [22]. Health 
system related reasons for LTFU were  poor record keeping and appointment 
scheduling procedures, inadequate capacity at the colposcopy services and a lack 
of client tracking systems [22]. Client reasons for non-attendance were, however, 
not explored. Similar findings were noted in another South African study 
conducted in the Western Cape where a 33% LTFU in colposcopy attendance was 
recorded in 2009 [23]. Patient reasons for non-attendance in this study were not 
investigated.
The literature identifies many factors which contribute to LTFU following an 
abnormal Pap smear. The majority of these studies have, however, been 
conducted in developed country settings. These factors have broadly been 
classified into individual, health system, psychosocial and community factors [19, 
24]. Individual factors include socio-demographic and patient level factors [19, 
24]. Psychosocial factors include clients’ feelings and experiences [19, 25]. 
Health system factors include provider communication, administration procedures 
and client tracing [26]. Community factors include population characteristics, and 
cultural values and beliefs [24, 27].
Either being very young (<30 years) or older (>55 years) has been shown to 
negatively impact follow-up care (colposcopy or treatment) of an abnormal Pap 
smear [24, 28]. Being very young was associated with a lack of knowledge or 
understanding of cervical cancer as well as being less exposed to gynaecological 
interventions compared to older women [8]. Lesion severity has also been shown 
to influence colposcopy attendance [19]. Women with more severe lesions (HSIL) 
were more likely to attend a colposcopy follow-up to women with lower grade 
lesions [29]. 
A study conducted in the US showed that lower levels of education, being 
unemployed or having a low income negatively influenced colposcopy   
attendance [30]. In contrast, other studies have shown no association between age, 
level of education and colposcopy attendance [21, 31]. In studies from the US, 
5personal factors that influenced colposcopy attendance included concerns about 
fertility, family responsibility, disruption of work, and transport difficulties [24, 
26]. 
The most common psychosocial factors identified in studies involving barriers to 
colposcopy were fear and anxiety [24, 26]. This includes: anxiety and fear with 
regard to the procedure, fear of the unknown or what the diagnosis may be, fear of 
having cancer, not understanding the meaning of the smear result or meaning of 
the test, fear of death, and fear of not being able to take care of oneself or family 
due to ill health [19, 25, 32]. In a US study, Schoenberg et al [24] reported that a 
fear of cancer along with having knowledge of the importance of follow-up care 
facilitated a group of women to attend their follow-up appointment (repeat Pap 
smear, colposcopy or treatment), whereas, it deterred others from seeking follow-
up care. In a South African study, Moosa et al [33] showed that 50% of women 
presenting at a colposcopy clinic had elevated anxiety scores, however, reasons 
for the anxiety were not explored. Limited South African data on the psychosocial 
factors influencing colposcopy attendance are available.
In studies from the US and the United Kingdom, health system factors reported to 
influence follow-up care included: long waiting times for a colposcopy 
appointment; the gender of the colposcopist [34]; and poor provider 
communication with regard to the procedure, explanation of the results and the 
diagnosis [19, 26]. Women attending colposcopy appointments reported that time 
spent with a provider before the procedure; being given explanations about the 
procedure and the results, and being provided with choices during the consultation 
offered reassurance and decreased anxiety, as well as contributed to positive 
experiences relating to colposcopy [25]. In South African studies, health system 
barriers reported to influence colposcopy attendance include Pap smear results not 
being communicated to patients, inadequate record keeping, and failure to book 
colposcopy appointments [22, 23].  Factors giving rise to these administrative 
failures in South Africa need to be further explored.
Community factors also impact on adherence. These factors include patient 
concern regarding confidentiality among close knit communities, particularly in 
rural areas; lack of community awareness about seeking follow-up care, and 
6cultural beliefs [24]. Information on community factors influencing colposcopy 
attendance in South Africa is not available.
2. Justification:
Colposcopy adherence is a major problem in developing countries. The literature 
has identified many factors contributing to colposcopy non-attendance. However, 
the majority of these studies are quantitative and were conducted in developed 
countries. The different country contexts and health systems mean that the results 
from these studies might not be applicable to South Africa. Qualitative studies 
exploring reasons why women in South Africa fail to attend their colposcopy 
appointment following an abnormal Pap smear result, and the knowledge and 
experiences of women attending colposcopy clinics in South Africa are limited. 
This study seeks to understand the reasons that influence women in attending their 
colposcopy appointments, both from client and provider perspectives. A better 
understanding of these factors could enable health authorities to direct 
interventions towards these barriers and improve colposcopy attendance.
3. Aim of the Study:
To explore barriers and facilitators to attending colposcopy assessment following 
an abnormal Pap smear result among women in Cape Town, South Africa. 
3.1 Objectives:
1. To develop an understanding of why women fail to attend colposcopy 
assessment following an abnormal Pap smear result.
2. To explore knowledge and experiences of women with an abnormal Pap smear 
result referred to colposcopy assessment.
3. To explore barriers and facilitators to colposcopy attendance by women 
following an abnormal Pap smear result from a health provider perspective.
74. Methodology
4.1 Study design:
This will be a qualitative exploratory study informed by McLeroy’s ecological 
model [35]. McLeroy’s ecological model is a variation of Bonfrenbrenner’s 
ecological model of 1979. It provides a framework for understanding health 
behaviour and is based on multiple interacting levels of influence [36]. The model 
views behaviour as affected by and affecting the social environment. The 
ecological model looks at the interrelationship between five levels [35]:
1. Intrapersonal or individual level: includes characteristics of the individual, 
such as skills, knowledge, experiences, or anything occurring within the self or 
the mind.
2. Interpersonal level: includes formal and informal social networks and social 
support systems, for example friends, family and workgroups. 
3. Institutional or organisational level: is concerned with how organisational 
groups can influence behaviour change. It includes: social institutions, with 
organisational characteristics; formal and (informal) rules for operation and 
regulation; for example work organisations.
4. Community level: includes relationships between organisational institutions 
and informal networks within defined boundaries, for example church groups and 
voluntary associations which influence the larger community values, beliefs and 
norms.
5. Policy level: includes local, state and national policy and laws.
The ecological model together with the literature will be used as a framework to 
better understand the reasons why women fail to attend their colposcopy 
appointments and to determine the knowledge and experiences of women referred 
to colposcopy. The model will be used to guide the research and formulation of 
the data collection tool. For the purpose of this research, the intrapersonal level 
will include individual factors, feelings and experiences. The interpersonal level 
will include relationships and social support. The institutional level will address 
health system factors, and the community level will include beliefs and cultural 
8and environmental influences. The policy level will not be explicitly explored due 
to the scope of this research.
4.2 Population and sample:
The study will take place at the Groote Schuur Colposcopy clinic. Groote Schuur 
Hospital (GSH) is one of the main referral centres for colposcopy services in Cape 
Town and serves a wide catchment area. Colposcopy clients will be recruited 
from the colposcopy clinic. Health care providers from the two main primary 
health care referring clinics viz. Cross Roads Clinic and Nolungile Day Hospital 
will be included in the study.
4.3 Sampling and recruitment:
A total of 24 female colposcopy clients 18 years and older will be selected. 
Respondents will comprise of 12 colposcopy attendees and 12 non-attendees. 
Non-attendees will be identified by reviewing the colposcopy clinic diary in 
consultation with the administration assistant. Clients that have not attended their 
appointment date will be telephonically contacted to participate in the study. 
Verbal consent will be obtained followed by a telephonic interview. New 
colposcopy clinic attendees at the colposcopy clinic will be recruited and 
interviewed on site. Clients will be purposively selected according to the inclusion 
criteria. Since the purpose is to collect data rich in depth, the final sample size will 
also be determined when a point of saturation has been reached [37].
Health provider interviews will comprise of eight participants:
a.) Three health care providers from the GSH colposcopy clinic: one 
colposcopist, the head of colposcopy clinic and a colposcopy nurse. 
b.) The administrative assistant at the GSH cytology laboratory who makes the 
colposcopy bookings based on the Pap smear results.
c.) Providers from the two primary clinics. This will include the clinic manager 
and a nurse who performs Pap smears (cervical screening) from each of the 
clinics. 
9The providers will be purposively selected in order to gain insight into the barriers 
and facilitators to colposcopy clinic attendance. Providers will be recruited to 
participate in the study and consent will be obtained.
A pilot study will be done with two colposcopy clients attending the colposcopy 
clinic. In-depth interviews will be conducted to test the interview guide and to 
ensure participants' understanding of the questions. The pilot will also give input 
on the duration of the interview and an idea of the data analysis.
Inclusion criteria for clients:
- Women 18 years and older
- Referred to colposcopy due to an abnormal Pap smear result
- First time colposcopy attendee
- Ability to comprehend and communicate in English or Afrikaans 
- Ability to provide consent
Exclusion criteria:
- Women younger than 18 years of age
- Previous cervical cancer
- Unable to speak and understand English or Afrikaans 
Inclusion criteria for health care providers or key informants:
-Involved in some way in providing colposcopy services to patients
4.4 Data collection:
In-depth, individual, face-to-face interviews will be conducted with clients 
attending the colposcopy clinic, and telephonic, in-depth interviews with non-
attendees. In-depth interviews were chosen as it is useful to explore personal 
experiences and perspectives on sensitive issues as well as ensuring 
confidentiality due to interviews being one on one [37]. Client interviews will be 
semi-structured using an interview guide (Addendum 1) with open-ended 
questions. This will allow for some flexibility, but also provide structure to the 
interview [38]. Client files will be reviewed for information regarding the date of 
the Pap smear, the Pap smear result and the referring clinic. An information sheet 
10
(Addendum 2) will be used to collect demographic information including age; 
employment status; level of education; number of children; and marital status. 
Interviews will take about forty five minutes each and involve questions covering 
individual, interpersonal, health system and community factors relating to 
colposcopy attendance as outlined by the ecological model [35] and the literature 
[24]. Individual factors will include, questions involving personal factors such as: 
client experiences; feelings; and knowledge of colposcopy, cervical cancer, and 
Pap smears. Interpersonal factors will include questions on social and family 
support. Health system factors will include questions on scheduling of the 
colposcopy appointment and provider communication. Community factors will 
include questions involving culture and beliefs. Interviews will be recorded with 
permission of respondents. These interviews will be conducted in a quiet room at 
the colposcopy clinic to ensure privacy.
In-depth individual interviews with health care providers at the colposcopy clinic 
and the referral clinics will be conducted using an interview guide (Addendum 3, 
4, 5 & 6) with open ended questions. Interviews will cover questions relating to 
barriers and facilitators to colposcopy attendance from a provider’s point of view.  
The duration of provider interviews will be about 30-40 minutes. Interviews will 
take place in a room at the colposcopy clinic and at the referring clinics for clinic 
staff. All interviews will be conducted by the main researcher in English or 
Afrikaans. 
4.5 Data management:
All interviews will be recorded with a digital recorder with client and provider 
consent. In addition, field notes will be taken by the researcher. All recordings and 
field notes will be transcribed onto computer files using Microsoft Office. Any 
recordings and field notes in Afrikaans will first be transcribed, then translated 
onto computer files. Data will be transcribed as they are collected (iterative 
process). A copy of the files will be stored on a flash drive. All materials required 
for data collection, such as consent forms; interview guides; field notes; pens; and 
recorder; will be stored in big brown envelopes and labelled for convenience, on 
the day interviews are conducted. All materials and data collected will be stored in 
a secure place, which no one else will have access to, except the main researcher. 
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Each interviewee will be given an archival number which will be noted on each of 
the forms used for the interviews and stored in the envelopes. An archival log 
(Addendum 7) will be used as a data tracking form for interviews.
4.6 Data analysis:
The transcribed data from interviews and field notes will be entered into a
qualitative computer software package, Atlas Ti version 6 (Scientific Software 
Developments, Berlin, Germany). Thematic analysis will be used to analyse the 
data. Thematic analysis is a method whereby codes are derived from the data [39]. 
Codes are used to form basic themes, the basic themes are then clustered to form 
organising themes, which are more specific than basic themes and encompasses a 
set of ideas [40]. Organising themes are then clustered to form global themes 
which explain what the text as a whole is about [40]. Similarities and differences 
across the data will also be assessed. The software will be used to identify data 
that support the themes. All data will be collected and analysed by the main 
researcher. Any uncertainties about themes and analysis will be discussed with a 
supervisor and co-supervisor to ensure accuracy. The co-supervisor will check 
themes by assessing a few transcripts to validate the correct interpretation of data.
4.7 Ethical considerations
The research complies with the Declaration of Helsinki (2008). The proposal will 
be submitted to the University of Cape Town Health Sciences Human Research 
Ethics Committee for approval. Permission to conduct the study will also be 
obtained from the City of Cape Town Department of Health, GSH, and the 
referring primary health care facilities.
Participant consent will be obtained on recruitment. A consent form will be 
provided for client attendees at the colposcopy clinic, as well as for providers. All 
information with regard to the procedure and details of the study will be provided 
on the consent form attached in the appendix (Addendum 8 & 9).
Verbal consent will be obtained telephonically from the non-attendee clients. To 
respect autonomy, participation in the study is voluntary and participants may 
decline to participate. Participants will not be penalised for declining and will still 
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receive all services entitled to them. They will be informed that they may 
withdraw from the study at any stage without penalty.
If participants agree to participate, all information collected will be strictly 
confidential and will only be shared with the supervisor and co-supervisor. To 
maintain anonymity participants’ names will not be recorded, but rather, each will 
be given a study number. For the purpose of telephonic interviews, names of 
potential clients will be taken down from the colposcopy register, but, as 
telephonic interviews are completed names will be erased and replaced by a study 
number. If participants do not want the interview to be recorded, recordings will 
be stopped. 
There are no foreseeable risks involved in participating in the study except that it 
may induce questions of uncertainty or queries with regard to the procedure, 
which can be addressed by the colposcopist. There are no direct benefits for 
participating, except that clients will be given a light refreshment. The results of 
the study can assist the wider community and provide better insight into how 
colposcopy services can be improved, to ensure that more women attend their 
follow-up appointments. To ensure accountability participants will be provided 
with the number of the UCT Human Research Ethics Committee and the main 
researcher, whom they may feel free to contact if they have any queries with 
regard to the study.
4.8 Limitations: 
The study is being conducted at one tertiary hospital colposcopy clinic due to 
feasibility and time constraints and this could limit generalisation of results. 
Clients that speak only Xhosa will be excluded, as the researcher does not speak 
Xhosa and has chosen to conduct all interviews. The expected sample size may 
not be achieved; either due to respondents not fulfilling inclusion criteria, not 
attending appointments or being uncontactable, particularly, the clients being 
telephonically interviewed. Every effort will however be made to obtain contact 
numbers even if it necessitates contacting the referring clinic and asking for 
contact numbers. Data collected and analysed by one researcher could introduce 
researcher bias, but, data analysis will be discussed with a co-supervisor.
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4.9 Generalisability
Qualitative research is not primarily concerned with results that are generalisable, 
but, the results from this study can be applicable to similar contexts in South 
Africa, where women are from low socio-economic backgrounds and users of 
government services. 
4.10 Reflexivity
The principal researcher has a physiotherapy background with an interest in 
women’s health and experience in clinical physiotherapy and rehabilitation. 
Having this background will assist in understanding clients’ experiences in the 
hospital setting. To ensure reflexivity the researcher’s ideas and thoughts will be 
separately recorded from participants’ views.
5. Data Logistics:
5.1 Research team
All data will be collected, transcribed and analysed by the main researcher. The 
write up and dissemination of results will also be the responsibility of the main 
researcher.  A supervisor will oversee the research project and a co-supervisor 
with experience in qualitative research will provide input with the analysis.
6. Write up and Dissemination: 
Once the results have been analysed and written up, a meeting with health 
authorities will be arranged. Management and health providers from the 
colposcopy clinic and the two referring clinics will be invited to attend a 
presentation of the research results. It is intended that the research be presented to 
the Western Cape Provincial Department of Health to provide feedback on the 
research results. An electronic copy of the results will also be sent to the health 
care facilities included in the study.
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2PART B: LITERATURE REVIEW
Barriers and Facilitators to Colposcopy Attendance Following an 
Abnormal Pap Smear Result
1.  Introduction
The objective of this literature review is to summarise key issues relating to 
challenges in the implementation of cervical cancer screening programmes in 
developing countries, particularly South Africa, with a focus on barriers and 
facilitators to follow-up of abnormal Papanicolaou (Pap) smear results. The 
literature review includes the following: 
 The burden of cervical cancer in developed and developing countries.
 The prevention of cervical cancer, including the natural history of cervical 
cancer and primary and secondary prevention. 
 Barriers and facilitators to follow-up of an abnormal Pap smear, including 
individual, psychosocial, health system and community factors.
An online journal search was conducted in Scopus, Pubmed, Medline and Google 
Scholar for articles relating to barriers and facilitators to the follow-up of 
abnormal Pap smear results. The World Wide Web was used to search the grey 
literature. Search terms included “cervical cancer AND risk factors”; “cervical 
cancer AND natural history”; “barriers OR non-adherence AND colposcopy 
follow-up”; “adherence OR loss to follow-up and colposcopy”, “abnormal Pap 
smear follow-up”; and “adherence AND cervical cancer screening follow-up”. 
Publications from 1978 to 2013 were selected from the above search engines. 
Articles were scanned by reading the abstracts. If the abstracts included any terms 
relating to barriers or facilitators to colposcopy attendance or follow-up of an 
abnormal Pap smear, it was selected for the review. Articles in which follow-up 
care had not included a colposcopy assessment were excluded. The reference lists 
of journal articles were used to identify additional articles. Qualitative and 
quantitative articles as well as articles from developing and developed countries 
were included to compare factors influencing colposcopy adherence between the 
different countries.
32.  Burden of Disease
Cervical cancer remains a public health problem, particularly in developing 
countries. It is the second most common cancer following breast cancer, among 
women globally [1]. In 2012 there were an estimated 527 624 new cervical cancer 
cases and 265 653 deaths [2], with more than 85% of cases occurring in 
developing countries [3]. Cervical cancer comprised 9% of all cancer cases and 
8% of all cancer deaths among women worldwide in 2008 [4]. The greatest 
cervical cancer burden occurs in sub-Saharan Africa, South America and South-
Central Asia with age standardised incidence rates (ASIR) in these regions 
ranging between 24 to 34 per 100 000 women [3, 5].
In developed countries, mortality and morbidity associated with cervical cancer 
has decreased, due to the successful implementation of organised cytology-based 
screening programmes [6] in which precancerous lesions are detected and treated 
[7]. A sharp decline in cervical cancer mortality has been seen in Nordic 
countries, due to the widespread implementation of organised screening 
programmes [8, 9]. In Iceland, the age standardised mortality rate (ASMR) for 
cervical cancer decreased from 23.1 per 100 000 in the late 1960s to 14.6 per 
1000 000 in the early 1970s [10]. For the period 1965-1981, mortality due to 
cervical cancer dropped by 80% in Iceland, 50% in Finland, 34% in Sweden and 
10% in Norway [8]. The greatest impact in mortality rates was achieved in 
Iceland, due to the widest coverage of the programme [9]. 
The effectiveness of an organised cervical screening programme was also 
observed in England. After implementation of the programme, screening coverage 
increased from 45% in 1988 to 85% in 1994 [11]. Cervical cancer incidence 
dropped from 16 per 100 000 women in the 1980s to 10 per 100 000 women in 
1994 and mortality decreased by nearly half over a ten year period (6.1 per 
100 000 in 1987 to 3.7 per 100 000 in 1997) [11] . 
These findings support the view that the decline in cervical cancer incidence and 
mortality rates in developed countries were due to organised screening 
programmes including a high screening coverage.
In contrast, in developing countries the incidence of cervical cancer remains high 
due to a lack of screening or poorly organised screening programmes [12]. Many 
4of the health providers in developing countries display a lack of knowledge about 
the aetiology of cervical cancer thereby influencing patient management [13, 14].
In an Asian study, 56% of providers associated poor personal hygiene as a cause 
of cervical cancer [13].
There are no organised cervical screening programmes in sub-Saharan Africa 
apart from South Africa [12]. Cervical screening in sub-Saharan Africa favours 
younger women accessing gynaecological and antenatal clinics and often does not 
reach older women who are at higher risk [15, 16]. 
An analysis of time trends indicates that cervical cancer incidence remains high in 
sub-Saharan Africa [17]. In 1990 the ASIR per 100 000 women was 40.4 in 
Southern Africa, 37.4 in Eastern Africa and 26.2 in Western Africa  [17]. In 
Southern and Eastern Africa incidence rates have decreased, but are still high 
compared to developed countries, with an ASIR per 100 00 women of 26.8 in 
Southern Africa and 33.7 in Eastern Africa in 2008 [3] . In Western Africa, the 
ASIR has increased to 34.5 per 100 000 women in 2008 [3]. The consistently high 
cervical cancer incidence could be partially due to a low population screening 
coverage and poor access to treatment for precancerous lesions in most parts of 
Africa [16, 18]. In Africa, the highest cervical cancer mortality rate is in Southern 
Africa with an ASMR of 14.8 per 100 000 in 2008 [3].
Data on cervical screening coverage rates are lacking in Africa. Very limited 
cervical screening occurs in most parts of Africa [18]. In 1997 a study conducted 
in Uganda, Tanzania, Lesotho, Kenya and Zimbabwe reported that, across the five 
countries, on average only four Pap smears per month were performed at the 
primary level, twenty per month at the district and provincial hospitals and 86 per 
month at the tertiary hospitals [16]. An absence in policy guidelines, a shortage of 
laboratory infrastructure, limited trained health providers, a lack of resources and 
other health priorities contributed to this low screening coverage.
In South Africa, cervical cancer is the second leading cause of cancer among 
women [1]. It is estimated that 5 743 new cases and 3 027 deaths occurred in 
2008, with an ASIR of 26.6 per 100 000 women [5]. The highest incidence rate 
was among black women with an ASIR of 29.46 per 100 000 compared to 13.5 
per 100 000 in white women in 2006 [19]. The number of new cases and deaths of 
5cervical cancer in South Africa are projected to increase by more than 21% and 
27% respectively by 2025 if current trends continue [1]. For example incidence is 
projected to increase from 5743 in 2008 to 7329 in 2025. 
An analysis of time trends shows there has been no marked decrease in cervical 
cancer incidence in South Africa. Between 1993 and 1995, the ASIR for cervical 
cancer was 22 per 100 000 women, though the incidence in black women was the 
highest, with an ASIR of 27 per 100 000 women [20]. Cytology screening in the 
public sector was mainly available in antenatal and family planning clinics 
serving primarily younger women at lower risk [21]. The high cervical cancer 
incidence, particularly among black women, is perhaps due to the unequal access 
to cervical screening during the apartheid era [7]. Since 1993 the incidence of 
cervical cancer has been consistently high, with an ASIR of 28.7 per 100 000 
women reported in 1999 [22]. A marginal decrease was, however, observed in the 
early 2000s, but the incidence was still high compared to developed countries, 
with an ASIR of 22.75 per 100 000 women reported in 2003 [23]. Whether this 
was a true decrease or difficulties regarding the accuracy of the National Cancer 
Registry data are not known.
In summary, cervical cancer remains a major burden of disease in South Africa 
and other developing countries in Africa, due to a lack of, or poorly organised, 
screening programmes. 
3.  Prevention of Cervical Cancer
3.1 Natural history of cervical cancer
The natural history of cervical cancer (outlined in Figure 1) serves as a basis for 
the development of prevention strategies. Cervical cancer is caused by persistent 
infection of the cervix with high-risk human papillomavirus (HPV) which is 
transmitted sexually [24]. HPV has been recognised as a necessary but not 
sufficient cause of cervical cancer [25]. HPV infection may resolve spontaneously 
or develop into low grade squamous intraepithelial lesions (LSILs) [26]. The 
majority of LSILs resolve within two to three years [27]. However, a LSIL can 
progress into a high grade squamous intraepithelial lesion (HSIL) [28]. The 
majority of HSILs will advance to invasive cancer [27]. The progression from 
6precursor lesions to invasive cancer occurs over a period of 10 to 20 years [29]. 
The slow advance from precancerous to cancerous lesions allows for sufficient 
time to intervene and prevent the development of cervical cancer [30].
Risk  factors influencing the progression to cervical cancer include co-infection 
with other sexually transmitted infections such as  chlamydia trachomatis, 
neisseria gonorrhoea, human immunodeficiency virus (HIV) [31] and herpes 
simplex type 2 [32];  long term contraceptive use (> 5 years) [33]; cigarette 
smoking [34] and multiparity [35].
HIV increases the risk of persistent HPV infection, cervical precancerous lesions 
and cervical cancer [36, 37]. South African studies have shown that HIV positive 
women are five times more likely to be infected with HPV than HIV negative 
women [36, 38]. Infection with high risk HPV has been associated with immune 
suppression [37]. Research has also shown that HIV positive women are more 
likely to present with invasive cervical cancer ten years earlier than HIV negative 
women [39]. The link between HPV and HIV further highlights the importance of 
cervical screening and follow up of HIV positive women with abnormal Pap 
smears. This is particularly important to South Africa due to the HIV burden (5.7 
million adults) with more than 50% of adults infected with HIV being women 
[40].
Figure 1.
CIS, carcinoma in situ; CIN, cervical intraepithelial neoplasia; HPV, Human Papilloma virus; 
LSIL, low grade squamous intraepithelial lesion; HSIL, high grade squamous intraepithelial 
lesion; HR, high risk.
3.2 Primary 
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83.3 Secondary prevention
Secondary prevention stops the progression of disease from precursor lesions to 
invasive cancer [46]. Various secondary screening methods have been used for the 
detection of cervical cancer precursor lesions. The most commonly used tests are 
the Pap smear, HPV DNA testing and visual inspection with acetic acid (VIA) 
[47]. The Pap smear remains the most widely used screening test and involves 
collecting endocervical cells with a spatula or brush for microscopic examination 
for detection of precursor lesions [46].
Women with abnormal smears (HSILs and persistent LSILs) require a colposcopy 
assessment [12]. Colposcopy is a specialised procedure using a colposcope with a 
strong light to examine the uterine cervix for cervical abnormalities; it allows a 
biopsy to be obtained for a histological diagnosis [48]. Follow-up and treatment of 
precursor lesions are critical steps in the secondary prevention of cervical cancer. 
Developing countries face many challenges implementing an effective cytology-
based screening programme [12]. Some of these challenges include: human 
resource shortages, resource constraints, poorly functioning health systems [49], a 
lack of access to health services particularly by women of low socioeconomic 
status (SES) living in rural or urban areas, and competing health priorities [16, 
50]. A key challenge is poor colposcopy clinic attendance following an abnormal 
Pap smear [51]. 
A National Cervical Cancer Screening Policy was introduced in South Africa in 
2000 [52]. The screening policy states that women between the ages of 30-60 
years are entitled to three free Pap smears in their lifetime, ten years apart. The 
objective of the policy is to decrease the number of new cases of cervical cancer 
by identifying and treating the early stages of the disease. The goal of the policy is 
to screen at least 70% of women within the target age within 10 years of 
commencing the programme. Theoretically, if well implemented, the policy has 
the potential to reduce cervical cancer incidence by 67% [53].  South Africa is yet 
to reach this goal. Compared to the United States Cervical Cancer Screening 
Guidelines, recommends that women between the ages of 21-65 years be screened 
with cytology every 3 years [54]. Screening every 3 years has been associated 
9with a life time risk of cancer of approximately 5 to 8 incident cases per 1000 
women and a life time risk of death of 0.05 per 1000 women [54]. 
Over the past few years cervical screening coverage has gradually increased in 
South Africa from 18% in 2003 [55] to 55% in 2011 [56]. Implementation of the 
policy has been challenging due to a lack of  provider knowledge about the 
screening policy, cervical cancer, and the  management of clients with abnormal 
Pap smears [50, 57]; poor community knowledge and awareness regarding Pap 
smears and cervical cancer; low literacy levels [58-60]; fear of the Pap smear 
procedure and not feeling ill [61] were among a few reasons reported.
The ultimate goal of cervical screening is the prevention of cervical cancer; this is 
only beneficial if women with abnormal smears are appropriately investigated (at 
the colposcopy clinic) and treated [62].  If women with abnormal Pap smears do 
not attend follow-up sessions, this will result in a decrease in screening 
effectiveness, reduce the efficiency of health care resources, and increase 
programme costs [63].
Loss to follow-up, non-adherence and default to follow up an abnormal Pap smear 
have been used interchangeably in the literature and have been defined in the 
proposal (Section A page 3). Loss to follow-up (LTFU) rates of between 33% and 
58% of women with abnormal Pap smears have been reported in South Africa [50, 
64-66]. A study in Gauteng identified LTFU to be over 50% among women who 
were referred to colposcopy with high grade lesions [66]. Reasons that woman 
were lost to follow up were due to poor health system performances such as poor 
record keeping and appointment making procedures, and inadequate capacity of 
the colposcopy services. In this study, client reasons for non-attendance were, 
however, not explored.  
Similar findings were documented in The Cervical Health Implementation Project 
(CHIP), conducted between 2001 and 2003 in three provinces in South Africa 
[50]. This study found that 50% of women with HSIL who were referred to 
colposcopy were lost to follow up [50]. The high rate of LTFU in CHIP was 
partially attributed to inadequate client tracking. A slightly lower rate was 
detected in another local study in the Western Cape, South Africa, with a 33% 
LTFU among women referred for colposcopy in 2009 [65]. These studies have 
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provided some quantitative data on the extent of poor colposcopy clinic 
attendance. However, there is limited information on reasons for poor attendance 
in South Africa. 
In summary, primary and secondary prevention strategies for cervical cancer 
exist. The main objective of secondary prevention is the early detection and 
treatment of precursor lesions. Unless precursor lesions are followed up, screening 
efforts are futile. Secondary prevention will remain an important strategy for 
many years. LTFU of women with abnormal Pap smears remains a significant 
challenge in South Africa. The next section reviews the literature on barriers and 
facilitators to follow-up of abnormal Pap smears.
4. Follow-up of Abnormal Pap Smears: Barriers and Facilitators
In a systematic review from the US, Eggleston et al [67] reported on adherence 
rates to follow-up of an abnormal Pap smear of between 27% and 90%. This wide 
range is due to the different definitions used in the literature. In Ontario, Canada, 
where the requisite time for follow-up of high grade abnormalities (colposcopy or 
treatment) is two to six months, adherence rates were 60% at three months and 
83% at six months [68]. A lower adherence rate at three months is suggested to be 
due to system issues including a lack of resources to meet the demand of women 
requiring follow up of high grade lesions. The South African screening policy 
does not provide guidance on the requisite time between an abnormal Pap smear 
diagnosis and time seen at the colposcopy clinic [52].
Barriers and facilitators to colposcopy attendance have been reported to be 
influenced by multiple interrelating individual, psychosocial, health systems and 
community factors [67, 69]. Individual factors include socio-demographic and 
patient level factors [67, 69]. Psychosocial factors include clients’ feelings and 
experiences [67, 70]. Health system factors include provider communication, 
administration procedures and client tracing [71]. Community factors include 
population characteristics, and cultural values and beliefs [69, 72]. 
4.1 Individual patient factors
Studies investigating barriers to follow-up of an abnormal Pap smear (colposcopy 
or treatment) found lesion severity [67, 73, 74], age, level of knowledge, 
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educational level, SES and employment to significantly influence follow-up 
attendance [67, 68, 75-77].
Women with HSIL or atypical glandular cells of undetermined significance 
(AGCUS) are more likely to attend follow-up appointments (repeat Pap smear or 
colposcopy) for an abnormal Pap smear compared to women with low grade 
lesions [73, 74].  In a study conducted in the US follow-up attendance at three 
months was 76% in women with HSIL compared to 57% in women with LSIL 
[78]. In a cross-sectional study from the US, lesion severity was, however, not 
significantly associated with adherence to recommended follow-up care [79].  It 
has been suggested that providers and patients view low grade lesions as less 
important to follow up compared to more severe lesions (adenocarcinoma and 
HSIL) [67, 74].
Age is a factor associated with follow-up attendance. Either being very young 
(<30 years) or older (>55 years) has been shown to negatively influence follow-
up (colposcopy or treatment) of an abnormal Pap smear [68, 69, 75, 77]. In a 
cohort study in the United Kingdom (UK), 6.7% of women defaulted colposcopy, 
of which 62% were between 20-29 years compared to 39% between 30-59 years 
[75]. Being very young was associated with a lack of knowledge or understanding 
of the purpose of screening and follow-up care, as well as being less exposed to 
gynaecological care [75]. Reasons for older women being non-adherent are not 
well understood, but a US study reported that older women were past the 
childbearing stage and were therefore less concerned about gynaecological 
conditions [69]. Further research regarding the influence of age on colposcopy 
attendance is required in South Africa, in order to ensure that women of all ages 
access colposcopy services.
Colposcopy non-adherence is more common among women with a low SES and a 
lack of knowledge of Pap smears, cervical cancer and the colposcopy procedure 
[68, 75-77]. A retrospective cohort study conducted in the US showed that 13% of 
women delayed care for an abnormal Pap smear partly due to a lack of knowledge 
of Pap smears and cervical cancer [80]. The women who delayed care had a lower 
educational level and income than the women who attended follow-up care. 
Similarly, studies from the US and the UK demonstrated that women with lower 
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levels of education were more likely to default colposcopy services than women 
with a post-school education [75, 76, 81].  In the same UK study, unemployed 
women were 2.7 times more likely to default colposcopy than women who were 
employed [75]. Women with a low SES often have a lack of access to health care 
services, lower literacy levels, limited knowledge of disease, and are at a greater 
risk of cervical cancer [18, 82]. However, other studies found no association 
between socio-demographic factors and follow-up attendance [51, 63, 79]. Studies 
have utilised different study designs and methods, possibly accounting for these 
differences.
Research exploring knowledge of women with abnormal Pap smears, referred for 
colposcopy is not available in South Africa. This information would assist with 
recommendations to improve colposcopy attendance. 
Personal factors influencing colposcopy attendance include: family responsibility, 
disruption of work, and transport difficulties [69, 71, 81]. In a qualitative study, 
health care providers serving rural communities from high risk areas in the US 
reported that patients often had to choose between daily necessities such as petrol, 
transport, childcare costs and seeking preventative care [72]. Non-attendance at 
colposcopy due to transport difficulties has been reported in South African studies 
[50, 65, 69]. Blankenberg [65] illustrated an 18% increase uptake in colposcopy 
attendance at a locally implemented colposcopy clinic in the Western Cape, South 
Africa, compared to when patients were referred to a distant referral hospital. 
It is important to identify whether women referred for colposcopy experience 
similar or different personal barriers in South Africa, so that colposcopy services 
can be made more accessible to women.
4.2 Psychosocial factors
Attending a colposcopy appointment to investigate an abnormal Pap smear result 
has been associated with psychological distress [63, 70, 83, 84] and colposcopy 
non-adherence [69, 75, 76, 80]. The most common psychosocial factors related to 
colposcopy non-adherence were fear and anxiety [63, 67, 69, 71]. This includes 
fear and anxiety with regard to the procedure, fear of the unknown, fear of having 
cancer, anxiety as a result of not understanding the meaning of the Pap smear 
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result [71, 76, 80, 81, 85], and fear of not being able to take care of oneself or 
dependants due to ill health [69].
Fear and anxiety have been described as both a barrier and a facilitator to follow-
up (colposcopy or treatment) attendance [69, 76]. In qualitative studies from the 
US and the UK, a fear of cancer and fear of the unknown had a negative influence 
on return for follow-up Pap smears, colposcopy appointments or treatment [69, 
76, 86].  Women with a family history of cancer were particularly fearful [69, 86]. 
In the US study, Abercrombie [86] reported that HIV positive women were fearful 
of an abnormal Pap smear result because of a greater risk of developing cervical 
cancer. For these women, the possibility of having another life-threatening disease 
was alarming and contributed to non-attendance. In comparison to rural
Appalachian women in the US, fear evolving from a family history of cancer, 
along with the knowledge of the importance of follow-up care, motivated a group 
of women to attend their appointments [69].
In a study conducted in Soweto, South Africa, more than half the women 
presenting at a colposcopy clinic had elevated anxiety scores [83]. Similar 
findings were reported in Swedish and UK studies [70, 84]. In the Swedish study, 
anxiety was significantly associated with a score rated as “unsatisfactory” in 
economic, living and working conditions [84]. In the South African study, socio-
demographic factors were not significantly associated with elevated levels of 
anxiety [83]. 
It is evident from these findings that women referred for colposcopy experience 
fear and anxiety. Reasons contributing to women’s fears related to a colposcopy 
referral need to be further explored in South Africa, so that clients’ fears can be 
addressed. 
Fear that the colposcopy procedure would compromise fertility and cause a 
miscarriage in pregnancy have also been reported as reasons for non-attendance 
among socially disadvantaged women in developed and developing countries [51, 
69, 76]. In a Nigerian study, 33% of women refused to attend a colposcopy 
appointment, mainly due to fear that the procedure would affect future fertility 
[51]. The women who refused colposcopy were mainly young and nulliparous and 
resorted to spiritual help from spiritual leaders and church pastors. In some 
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African cultures and religions in Nigeria and South Africa, children are seen as a 
form of economic and social security for the family as well as a continuation of 
the family name [87, 88]. Anything that would jeopardise pregnancy is therefore 
avoided [51]. This indicates the importance of determining women’s perceptions 
of fertility in relation to attending a colposcopy procedure. This will aid in the 
planning of education strategies to educate women on the safety of the colposcopy 
procedure. 
Anxiety is not only influenced by factual information about the colposcopy 
procedure, but also by experience, attitudes, concerns and beliefs [89]. In a study 
conducted in the UK, women reported that a positive, supportive staff attitude had 
improved their colposcopy experience and decreased their levels of anxiety [70]. 
In another study conducted in the US, social support received by women in 
response to an abnormal Pap smear result had improved adherence to follow-up 
care threefold [90]. The role of social support in facilitating colposcopy 
attendance has not been explored in South Africa.
Limited South African data on the psychosocial factors influencing colposcopy 
attendance are available. 
4.3 Health system factors
Studies in the US and UK have highlighted the following provider factors that 
influenced colposcopy attendance: the gender of the colposcopist, with preference 
for a female colposcopist [70, 76]; and poor provider communication with regard 
to the procedure, explanation of the results and the diagnosis [67, 70, 71, 76]. A 
US study among a low income population reported that women were more likely 
to follow up (with colposcopy or repeat Pap smear) when the results and treatment 
plan were explained and when colposcopy services were offered at the same clinic 
where the patient had had the Pap smear [91]. 
In a South African study the long waiting time for a colposcopy appointment due 
to limited colposcopy services was identified as a barrier to colposcopy 
attendance [66]. Other factors impacting on colposcopy attendance in South 
Africa include clients not being informed of Pap smear results; inadequate 
recordkeeping; failure to book colposcopy appointments; and a lack of client 
tracking [65, 66].  
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In an attempt to decrease LTFU in women with abnormal Pap smears, various 
patient tracking interventions have been introduced in different countries. In a 
randomised control trial in California, client tracking comprised of a nurse 
consultant that followed-up on clients with an abnormal Pap smear [92]. Tracking 
was aided by a computerised database which detected follow-up appointments 
within a certain time period. All clients in the trial were informed telephonically 
and in writing about an appointment for a colposcopy or repeat Pap smear. The 
intervention group received a reminder call before the follow-up appointment and, 
if the patient did not attend, the client was recalled to reschedule the appointment 
and the importance of attendance emphasised. The intervention group was four 
times as likely to attend a follow-up appointment at six months compared to the 
standard care group. Telephone reminders assisted by a computerised tracking 
database could be an effective strategy in tracing colposcopy clients in South 
Africa, if sufficient resources were allocated. This strategy would require 
functioning telephone systems, computerized systems and human resources. 
In another study conducted in a low resource setting in Cape Town, South Africa, 
LTFU of women for repeat cervical screening appointments significantly 
decreased by introducing community health worker (CHW) visits [62]. CHWs 
visited women at their homes if they had not attended their scheduled screening 
appointments. The home visits were more successful when they were done closer 
to the initial appointment date. LTFU was reduced by 15%, 29% and 26% at six, 
12 and 24 months respectively. Organised CHW visits could be utilised to trace 
non-adherent colposcopy patients in South Africa, which would probably cost less 
than treatment for late stage disease. However, there are currently too few CHWs 
to meet this demand [93].
Approximately 80% of South Africans consult traditional healers in conjunction 
with western medicine for their health related needs [94]. In a South African 
study, traditional healers expressed their willingness to exchange information and 
collaborate with western doctors in preventing cervical cancer [95]. By 
collaborating with western health care providers, traditional healers could be a 
valuable asset in encouraging women to attend colposcopy.
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4.4 Community factors 
Community factors identified in studies from the US and Nigeria as influencing 
adherence to follow-up care (repeat Pap smear, colposcopy or treatment) for an 
abnormal Pap smear include: patient concerns regarding confidentiality in close 
knit communities, particularly in rural areas;  lack of community awareness about
seeking follow-up care; and cultural beliefs [51, 69].
South African data on community factors influencing cervical screening practises 
are available [96, 97], but information on community factors impacting on 
colposcopy attendance are lacking. Cultural barriers and beliefs influencing 
cervical screening involve stigma associated with cervical cancer; embarrassment 
[97]; “opening the legs” being seen as shameful particularly by Xhosa-speaking 
women to whom it is unseemly for an older women to expose herself to a younger 
provider; and the belief that cervical cancer was caused by witchcraft [96].
In summary, colposcopy non-adherence remains a challenge even where the 
service is available. Women are faced with many barriers in accessing colposcopy 
services. The majority of studies are, however, quantitative and conducted in 
developed countries. Qualitative studies are important in understanding reasons 
for poor colposcopy adherence. 
5. Conclusion
Although cervical cancer is preventable, incidence and mortality rates remain 
high. Treating abnormal lesions detected on cervical screening can contribute 
towards decreasing incidence and morbidity associated with cervical cancer. Poor 
colposcopy clinic adherence is a major problem in developing countries and 
contributes to a decrease in screening effectiveness. Qualitative research exploring 
reasons for poor colposcopy attendance in South Africa is required. Little is 
known about women’s knowledge and experiences of abnormal Pap smears, 
cervical cancer and the colposcopy procedure in South Africa. This research will 
provide additional insights to better understand the factors influencing women’s 
attendance at colposcopy. It could also inform health care providers and 
policymakers about areas of system improvements and possible targeted 
interventions that could increase colposcopy attendance.
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2Barriers and facilitators to colposcopy attendance following an 
abnormal Pap smear in South Africa: A qualitative study 
exploring client and provider perspectives
Abstract
Background: Colposcopy adherence following an abnormal Papanicolaou (Pap) 
smear is a major problem in low- and middle-income countries, including South 
Africa. Cytology-based screening is only beneficial if women with abnormal Pap 
smears are followed up at the colposcopy clinic and treated to prevent progression 
to cervical cancer. The purpose of this study was to explore barriers and 
facilitators to colposcopy attendance following an abnormal Pap smear result. 
Methods: A qualitative, exploratory study was conducted at a public sector 
tertiary hospital colposcopy clinic and at two primary health care clinics in Cape 
Town, South Africa. The study was conducted between May and August 2013. 
Data collection included 32 semi-structured interviews: 12 face-to-face interviews 
with colposcopy clinic attendees, 12 telephonic interviews with colposcopy clinic 
non-attendees and 8 face-to-face interviews with health care providers. Client 
interviews explored barriers and facilitators to colposcopy attendance; knowledge 
and experiences of Pap smears, cervical cancer and the colposcopy procedure; 
scheduling of colposcopy appointments; provider communication; reasons for 
non-attendance; and community support and beliefs. Provider interviews explored 
barriers and facilitators to colposcopy attendance from a provider’s perspective; 
the colposcopy referral process; and provider challenges in the provision of Pap 
smear or colposcopy services. Interview data were analysed using thematic 
analyses.
3Results: The main barriers influencing colposcopy attendance were: poor levels 
of knowledge of the importance of a Pap smear and the colposcopy procedure; a 
lack of awareness of cervical cancer as a disease; a fear of cancer; the 
asymptomatic nature of the disease; and transport costs. Health system barriers 
included clients not informed of colposcopy appointments and therefore they did 
not attend; a disjointed system of colposcopy scheduling; and staff shortages 
which resulted in less time for client tracking. Factors which promoted 
colposcopy attendance included experiencing symptoms; a family history of 
cancer due to the experience with death; colposcopy services situated closer to 
clients; and social support received from family members.
Conclusion: Colposcopy attendance could be improved through interventions that 
address poor client knowledge, improve provider-client communication, bring 
colposcopy services close to clients and simplify the colposcopy appointment 
system.
Key words: cervical cancer, Pap smears, barriers, facilitators, colposcopy 
adherence, provider and patient perspectives, South Africa. 
4Background
Cervical cancer remains a public health burden, particularly in developing 
countries. It is the second most common cancer among women globally [1], with 
estimates of 527 624 new cervical cancer cases and 265 653 deaths worldwide in 
2012 [2]. The majority of cases (more than 85%) occurred in developing countries 
in 2008 [3]. In South Africa, cervical cancer is the second most common cancer 
among women [1] with an age-standardised incidence rate (ASIR) of 24.7 per 100 
000 women in 2006 [4]. The number of new cases and deaths of cervical cancer in 
South Africa are expected to increase by more than 21% and 27% respectively by 
2025 if current trends continue [1]. For example incidence is projected to increase 
from 5743 in 2008 to 7329 in 2025.
A reduction in cervical cancer incidence and mortality has been successfully 
achieved in developed countries due to organised cytology-based screening 
programmes and early treatment of precancerous lesions [5]. In contrast, the 
incidence of cervical cancer in developing countries remains high due to a lack of 
screening or poorly organised screening programmes [6], with inadequate referral 
systems and treatment of abnormal Papanicolaou (Pap) smears [7].
The South African Cervical Screening Policy entitles women between the ages of 
30 and 60 years to three free Pap smears in their lifetime, ten years apart [8]. The 
objective of the policy is to decrease the number of new cases of cervical cancer 
by identifying and treating the early stages of the disease. The policy guidelines 
state that abnormal Pap smears with high grade squamous intraepithelial lesions 
(HSIL), atypical glandular cells of undetermined significance (AGUS), or two 
consecutive Pap smears with persistent atypical squamous cells of undetermined 
5significance (ASCUS), or with low grade squamous intraepithelial lesions (LSIL), 
should be referred for a colposcopy assessment. 
High rates of loss to follow-up (LTFU) or non-attendance at colposcopy clinics 
have been reported, particularly in low-income regions [7, 9-11]. LTFU rates of 
between 33% and 58% have been reported in South African studies [7, 11-13]. 
The ultimate goal of cervical screening, which is the prevention of cervical 
cancer, is only beneficial if women with abnormal smears are treated and 
followed up [14].
Studies have highlighted factors influencing women’s attendance at colposcopy. 
However, the majority of these studies are international and quantitative. Factors 
influencing colposcopy attendance include individual, psychosocial, health 
system, community and cultural factors [15-18].
Limited South African data on the barriers and facilitators to colposcopy 
attendance following an abnormal Pap smear are available, particularly qualitative 
data. Little is known about women’s knowledge and experiences of an abnormal 
Pap smear result, cervical cancer and the colposcopy procedure in a South African 
setting. In order to improve colposcopy adherence, a better understanding of the 
factors that influence women’s attendance at colposcopy in South Africa is 
needed.  This could inform health providers and policymakers about areas of 
system improvements and possible targeted interventions that could improve 
colposcopy attendance rates. 
This study explored barriers and facilitators to colposcopy attendance following 
an abnormal Pap smear result. Perspectives of colposcopy clinic attendees, 
colposcopy clinic non-attendees and health care providers are presented. 
6Methods
Study design
A qualitative exploratory study was conducted, informed by McLeroy’s 
ecological model [19], as a means to explore barriers and facilitators that women 
with abnormal Pap smears face when accessing colposcopy services. The model 
provided a framework to understanding health behaviour based on multiple 
interacting levels of influence [20], namely: the individual/intrapersonal level, 
which includes any individual characteristics such as knowledge and experiences; 
the interpersonal level, which includes social networks and social support 
structures; the organisational level, which includes how organisational institutions 
affect health behaviour; the community level, which includes beliefs and 
community influences; and the policy level, which includes laws and policy [19]. 
The policy level was not explored in this study.
Study setting
The study was conducted between May and August 2013 at a public sector, 
tertiary hospital colposcopy clinic and two primary health care clinics providing 
cervical screening services, in the greater Cape Town area, South Africa.  
Organisation of Pap smear and colposcopy services 
In Cape Town, Pap smears are usually performed by nurses at primary health care 
facilities and sent to a centrally located cytology laboratory. Colposcopy services 
are primarily offered at tertiary and a few secondary hospitals and performed by a 
gynaecologist. Clients referred to colposcopy services from the two clinics 
included in this study were mainly referred to the tertiary hospital. A few clients 
7were also referred to a recently established colposcopy clinic situated in close 
proximity to one of the primary health care clinics. Pap smear results are usually 
available two to four weeks after the smear is taken and these are sent via courier 
services to the respective clinics. Women receive a follow-up appointment from 
the clinic provider to collect their Pap smear results. Women with an abnormal 
result that has not been collected should be contacted by the clinic provider.
The system of colposcopy scheduling is complex and disjointed. Furthermore, 
methods used to inform women of Pap smear results and colposcopy 
appointments are not standardised.
Study population 
A total of 32 in-depth interviews were conducted with participants selected from 
the three study sites. Participants were purposively selected to include 12 
colposcopy clinic attendees, 12 colposcopy clinic non-attendees and eight health 
care providers. Colposcopy clinic attendees were identified as clients with an 
abnormal Pap smear result who had attended their colposcopy assessment, 
irrespective if it was a rescheduled appointment or not. Colposcopy clinic non-
attendees were identified as clients with an abnormal Pap smear result who had 
failed to attend their colposcopy assessment. 
English or Afrikaans speaking clients, 18 years and older and booked for a first 
colposcopy visit, were eligible for the study. Colposcopy clients were identified 
from clinic folders and recruited at the colposcopy clinic prior to their 
appointment. A list of clients who failed to attend their appointment was obtained 
from the colposcopy clinic tracing team. Where possible, attempts were made to 
contact non-attendees before the tracing team did. Non-attendees were 
8telephonically contacted from the day following a missed appointment. Attempts 
to contact clients were made six times before contact was discontinued.
Providers included the clinic manager and a nurse performing Pap smears from 
each of the primary health care clinics, two doctors and a nurse from the 
colposcopy clinic and an administrative assistant from the cytology laboratory. 
Data collection 
Individual interviews with attendees and providers took place in a private room. 
Non-attendees were telephonically interviewed. All interviews were conducted in 
English or Afrikaans by the principal researcher. Interviews lasted between 20 to 
45 minutes for both providers and clients. Participant interviews were digitally 
recorded, translated where necessary and transcribed verbatim. 
Interview guides were open-ended and semi-structured. Key issues explored in 
both the attendee and non-attendee interviews included: barriers and facilitators to 
colposcopy clinic attendance; knowledge and experiences of Pap smears, cervical 
cancer and the colposcopy procedure; the scheduling of colposcopy appointments; 
provider communication; and family and community support and beliefs. Non-
attendees were further probed about reasons for non-attendance.
Client demographic information included age, educational level, employment 
status, marital status and number of children. Details of the Pap smear results 
were obtained from clients’ clinic folders.
Provider interviews explored barriers and facilitators to colposcopy attendance 
from a provider’s perspective; the colposcopy referral process; challenges in the 
provision of Pap smears or colposcopy services; and health system interventions 
to increase colposcopy compliance. 
9Ethical considerations
Written informed consent was obtained for the face-to-face interviews and verbal 
consent was obtained for the telephonic interviews. Confidentiality and anonymity 
were ensured. The study was approved by the University of Cape Town Health 
Sciences Human Research Ethics Committee and institutional approval was 
obtained from City Health Cape Town and the tertiary hospital management. 
Data analysis
The data were collected and analysed by an iterative process. This allowed for 
further refining of questions and exploration of additional issues. Thematic 
analysis was used to analyse the data. Thematic analysis is a process whereby the 
data are coded, organised into themes and clustered to form more specific themes, 
which illustrate what the text as a whole is about [21]. A software package Atlas 
Ti version 6 (Scientific Software Developments, Berlin, Germany) was used to 
organise the data into codes and to support themes. The data were read several 
times for broad emerging themes which were further condensed into more specific 
themes. Analysis for similarities and differences took place within and across the 
data. 
Results
The mean age of clients was 40.2 years (range 29-63 years), and was similar 
between the attendees and non-attendees. Eight (33.3%) of the clinic clients were 
married, two (8.3%) were widowed, ten (41.7%) were unmarried and four 
(16.7%) were divorced. Both the attendees and non-attendees had between one 
and four children. Thirteen (65%) of the clinic clients had completed grade twelve 
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and four (16.7%) had completed some form of post-secondary education. Half 
(50%) of the attendees and a third (33.3%) of the non-attendees were employed.
Themes identified as influencing colposcopy attendance included: levels of 
knowledge related to screening and cervical cancer; motivations associated with 
having a Pap smear and colposcopy attendance; fear and anxiety related to an 
abnormal Pap smear result and colposcopy procedure; personal factors including 
transport costs, work schedules and childcare responsibilities; health system 
factors including infrastructural barriers; and social support.
Knowledge levels
The majority of clients were unable to distinguish between cancer and cervical 
cancer. Attendees and non-attendees described cancer more broadly as a 
“dangerous disease”, incurable if detected at a late stage and fatal. A few 
attendees and non-attendees reported having heard of cervical cancer or “cancer of 
the womb”, but did not have detailed knowledge except that a hysterectomy could 
be performed if cancer was detected. Some clients were aware of other types of 
cancers such as breast, stomach, lung and oesophageal cancer. As reported by a 
clinic provider: 
Women are not aware of cervical cancer, the type of cancer that they are aware of 
and afraid of is cancer of the oesophagus, cervical cancer they don’t know.
Clients’ awareness of cancer or cervical cancer were influenced by community or 
family experiences of cancer, for example, death resulting from cancer; by 
information relayed at the clinics or via the media. Clinic providers did not always 
distinguish between the terms cancer and cervical cancer and in many instances 
these terms were not adequately explained. This created an awareness of cancer or 
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cervical cancer, but a lack of detailed knowledge or understanding of the disease. 
As indicated by a non-attendee: 
I heard at the clinic when they tell the people about cancer, they didn’t explain 
thorough, but they encourage us to come to the clinic.
The majority of attendees and non-attendees had a similar understanding of the 
importance of a Pap smear. Pap smears were identified as important for the 
detection of cancer in the womb or to determine any diseases of the womb, for 
example, sexually transmitted infections (STIs). A few non-attendees did not 
know what a Pap smear was. Among the non-attendees, a lack of knowledge of 
the importance of a Pap smear was associated with a poor understanding of the 
implications of an abnormal Pap smear result and hence the purpose of follow-up. 
Many attendees and non-attendees did not appear to understand the significance 
of an abnormal Pap smear result. Consequently, a few non-attendees were unable 
to differentiate between an infection and the abnormal Pap smear. This 
phenomenon was highlighted by a non-attendee: 
When I went for the Pap smear she [nurse] said she sees an infection thing….Now 
I don’t know what it really is….. 
The majority of clients displayed a lack of knowledge about the colposcopy 
procedure. A lack of client understanding about the procedure and the Pap smear 
result was reported to be due to an inadequate explanation or no explanation given 
by primary level providers, as reported by an attendee:
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The results of the Pap smear were not explained to me, they just said your results 
are out, they are referring you to the other hospital so that they can attend to 
you…
A colposcopy provider reported that part of the problem of non-attendance could 
be attributed to a lack of knowledge among primary level nurses about the natural 
history of cervical cancer and the management of precancerous lesions, thereby 
influencing patient counselling:
I think the problem is the vast majority of nurses doing Pap smears in the 
Cape don’t even know themselves why they are doing Pap smears and they 
are not giving the patients the right information.... They tell the patient when 
they have a HSIL and most of them tell them that they have cancer. Others tell 
them that they have an infection but no one talks about pre-cancer and 
treatable etc. So I think the level of knowledge of health care providers at 
primary level is very poor and then patients are not getting the right 
message…
Misinformation about an abnormal Pap smear result and cervical cancer 
received from primary level providers resulted in clients being fearful. This 
situation was reported by a colposcopy provider:
By the time they get to me some of them have the “beverasies” (shakes), they 
think they are going to die in a week. So they are not being messaged 
correctly, that’s part of the issue.... So I think it’s the way we counsel patients 
and I think well-informed patients treated with respect….are going to be 
compliant.
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A lack of client understanding about the result and the procedure was further 
influenced by difficulty comprehending the terminology used in the colposcopy 
letter. This phenomenon was demonstrated by an attendee:
She [nurse] gave me a letter with the results, I didn’t understand…I went to the 
internet cafe and took that big words and put it in there so that I can know what it 
is about.
Motivations for Pap smears and colposcopy 
Women experiencing symptoms such as uterine pain or irregular bleeding were 
more likely to attend colposcopy appointments than women who were 
asymptomatic and had had a Pap smear as part of a routine clinic check-up or a 
family planning service visit. Providers confirmed that a lack of symptoms made 
it difficult for women to understand the importance of Pap smear screening. The 
following was reported by a clinic provider:
Very few come for the Pap smear.... I think our people they only think that when 
they are sick, they get a medication. Things like Pap smear tests those things 
because they don’t feel anything they don’t really realise that it’s also important.
An absence of symptoms also contributed to clients not seeing the value in 
returning for Pap smear results, as highlighted by a clinic provider:
Some say they got no pains, nothing, so there’s no point in coming to collect the 
Pap smear results because she’s not feeling anything.
Fear and anxiety
The majority of clients reported fear in response to an abnormal Pap smear 
result and the colposcopy procedure. Fear of the unknown led to feelings of 
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anxiety. Clients feared having cancer due to the association with it being a 
terminal disease. Poor understanding of the meaning of the Pap smear result 
contributed to clients’ fears of having cancer. This view was demonstrated by 
a non-attendee:   
When she called me I felt bad ... I cried, I thought, oh no I have cancer. I just 
felt bad, I felt down, I was not happy the whole day....
Among non-attendees, a fear of cancer or fear related to the result was not 
explicitly stated as a reason for non-attendance, but it was a concerning issue 
for clients. Clients’ fears were influenced by the choice of words that 
providers used in notifying them of the results. Words such as “wound in 
uterus”, “cancerous”, and “positive results” were some of the terms used. 
A clinic provider reported that some patients did not return for Pap smear 
results due to “fear of the unknown”. Failure to return for results resulted in 
clients requiring colposcopy of being uninformed about a booked colposcopy 
appointment.
Feelings of fear were heightened by a family history of cancer, particularly 
cervical cancer, due to the distress experienced by the family member; death 
of a family member, or negative responses about cancer conveyed by others.
Fear experienced in this context resulted in a greater likelihood of attending 
the colposcopy clinic. Concern for the future well-being of children had also 
prompted women to attend the colposcopy clinic, as reported by an attendee:
…Just because I have a child that’s why I’m coming here [colposcopy clinic].
Lack of knowledge about the colposcopy procedure and possible outcome also 
contributed to clients’ fear and anxiety.  A non-attendee reported that the reason 
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for not attending her colposcopy appointment was partly due to “feeling a bit 
scared” of the procedure. 
A few clients were also concerned about possible pain associated with the 
procedure and past negative experiences associated with a pelvic examination, as 
highlighted by an attendee:
The only thing I’m worried about is getting hurt, I hate that because when I 
did the Pap smear I was bleeding for two days it was very sore ... That’s the 
one reason why I hate the gynaecologist! Just for that stuff.  I’ll rather do 
anything else but don’t scratch in there I hate that.
In contrast, a few attendees were more positive and viewed the colposcopy as 
an opportunity to be diagnosed and receive treatment or to be cured, and thus 
motivated clients to attend. 
Personal factors
Personal factors that influenced colposcopy attendance included transport costs, 
childcare responsibilities and interruption of work schedules. Both clients and 
providers reported that transport costs were an important barrier affecting 
colposcopy attendance. Some clients were unable to afford the transport costs and 
therefore had not attended colposcopy appointments. A few attendees mentioned 
having borrowed transport money in order to attend their appointment. 
A colposcopy provider working at both the tertiary and community colposcopy 
clinics reported an increased compliance and a reduced default rate at the 
community colposcopy clinic when the clinic was situated closer to the patient’s 
residence:
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... Having more local centres where the patient could actually go would 
increase their compliance quite a lot because as I am out in Khayelitsha there 
are lots of patients who have defaulted the colposcopy clinic, but they easily 
come to me because there’s no issues, not much expense, not much travelling 
issues and so on, then I have a good rate of patients that have appointments.
With regard to childcare responsibilities, a client reported that she had to find 
someone to take her child to school in order to attend her follow-up 
appointment. A non-attendee was also concerned about who would look after 
her baby if she had to attend her colposcopy appointment. Furthermore, 
interruption with work schedules and difficulty getting off work were 
additional barriers reported which influenced colposcopy attendance.
Health system factors
A myriad of health system factors and failures influenced colposcopy attendance. 
These factors included inadequate feedback of Pap smear results; a disjointed 
system of colposcopy scheduling; and a lack of resources, including staff 
shortages. A third of non-attendees reported that they had not been informed of 
their Pap smear results and colposcopy appointments and therefore had not 
attended colposcopy. This situation was highlighted by a non-attendee:
They didn’t give me results ... they didn’t ... If they told me my results and that I’m 
supposed to come on that 19th  [for colposcopy appointment]…, but they didn’t ... 
I’m not happy because that means they are not serious about my health.
Providers reported challenges in reaching clients to inform them of results and 
colposcopy appointments because of invalid contact details. One clinic 
provider reported success with clients in collecting their results by sending 
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text message reminders from her mobile phone. Clinics utilised CHWs to 
trace clients, but, results using this method were mixed, with some clinics 
reporting success and others difficulties, due to incorrect address details and a 
lack of human resources.
A few non-attendees only became aware of their abnormal results and a missed 
colposcopy appointment when contacted by the colposcopy clinic tracing team. 
This was confirmed by a non-attendee: 
No, I didn’t know about that [missed appointment]. I got a call yesterday from 
someone at Hospital X that I must be there Friday [new colposcopy 
appointment] because I was supposed to be there on the 28th.
Human resource issues such as staff shortages impacted negatively on colposcopy 
attendance. Staff shortages resulted in nurses having to allocate time to other 
duties and departments, thus leaving less time to follow up clients, as indicated by 
a clinic provider:
Out of the professional nurses there will be one that is on leave, one on a 
course and there’s always sick children to be seen, now we need to take 
nurses to see them, and one cannot cope……Maybe if you have time you think 
I can take out the folders for the people I’ve sent to colposcopy and check who 
went….But sometimes you never do it because you work till half past four and 
then never think of going and checking.
Furthermore, staff shortages contributed to long waiting times. A provider 
reported that spending a few hours in the clinic queue just to collect a folder and 
then to receive results was not an incentive for clients to return. It was therefore 
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suggested by a colposcopy provider that patients be called back for results once a 
week, bypassing the main clinic system of receiving results.
Staff shortages also influenced patients receiving their Pap smear results. A client 
reported that when she attended her follow-up appointment to receive her Pap 
smear result, the clinic nurse was on leave and no other provider was available to 
assist her. Consequently, the client had not received her results and had therefore 
missed her colposcopy appointment. 
Social support
Social support had a positive impact on client colposcopy attendance. Many 
clients attending colposcopy reported receiving encouragement and support from 
friends, family, employers, church groups and even health care providers to attend 
colposcopy. The following was illustrated by an attendee:
My sister is always saying if you go there for the treatment you will be fine, 
even my boss at work I tell them the result. They say if you go there for 
operation ... we’ll assist you with everything and my church members they 
come for prayer ... They just keep me company, they pray for me, they talk 
with me.
Many non-attendees lacked this support either due to a partner with a limited 
understanding of Pap smears or due to the client not wanting to confide in anyone.
Discussion
Poor colposcopy clinic adherence is a major problem in low- and middle-income 
developing countries, including South Africa. Poor adherence decreases screening 
effectiveness, denies other women earlier appointments, decreases the efficiency 
of health care resources and increases programme costs [22]. This study provides 
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insights into reasons for poor colposcopy adherence which, if addressed, could 
lead to early identification and treatment of women with precancerous lesions.
This study confirms findings from previous studies conducted in South Africa that 
women lack awareness of cervical cancer as a disease [23-25]. Clients were aware 
of other types of cancers, but very few were acquainted with cervical cancer. This 
lack of awareness about cervical cancer could be related to silence of the disease. 
The silence is influenced by cervical cancer not commonly been spoken about in 
the public, thus very few people have knowledge of the disease; poor provider 
communication and knowledge about cervical cancer and the asymptomatic 
nature of precancerous lesions. Wood et al [26] reported in a South African study
that among some cultures, women believed that cervical cancer had to be kept a 
secret because it involved the “underneath parts”. The silence relating to cervical 
cancer could impact on clients seeking follow-up care for an abnormal Pap smear 
and on the level of support that women receive from community members. 
Results from this study are in accordance with previous studies which show that a 
lack of knowledge of the purpose of a Pap smear contributes to non-attendance at 
colposcopy [18, 27-29]. A third of non-attendees had not received results directly 
from their clinic provider. This may have resulted in clients receiving less 
education about the Pap smear result, cervical cancer and the colposcopy 
procedure. However, clients should be educated about Pap smears and the 
importance of returning for results when a Pap smear is performed. A number of 
non-attendees were asymptomatic and had a Pap smear as part of a routine check, 
it is not clear whether the importance of a Pap smear was adequately conveyed in 
routine clinic check-ups. Importantly, Pap smears forming part of routine checks 
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should be accompanied by client education to ensure that clients understand the 
risk of cervical cancer and the importance of returning for Pap smear results. 
Being asymptomatic has been confirmed in other studies as a factor influencing 
screening and follow-up care [26, 30]. Not experiencing any symptoms leads to 
difficulty in accepting the possible presence of disease and could contribute to 
colposcopy non-attendance. This highlights that providers must place greater 
emphasis on explaining that even though women are asymptomatic they could 
still be at risk of cervical cancer and ensure that clients understand the importance 
of attending colposcopy follow-up care if required. By collaborating with western 
health care providers, traditional healers could be a valuable asset in encouraging 
women to attend colposcopy.
In our study, many women presented at the colposcopy clinic due to experiencing 
symptoms. This illustrates that women are keen to seek medical attention for a 
perceived physical condition. Being symptomatic could also be more fear 
provoking and encourage women in seeking a diagnosis. Our findings are similar 
to that of Wood et al [26], whereby, women predominantly attended cervical 
screening services due to experiencing physical gynaecological symptoms such as 
abdominal pain or vaginal discharge and were eager to find out the diagnosis to 
their problem. Given, that cervical precancer is asymptomatic greater efforts need 
to be made to make women and communities aware of the asymptomatic nature of 
precancer.
During the interviews many questions were raised by clients about an abnormal 
Pap smear and the colposcopy procedure, highlighting clients’ unmet need for 
information. A similar finding was reported in a South African study exploring 
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women’s experiences of being diagnosed with cervical cancer [31]. Women 
yearned for additional information relating to cervical cancer in order to increase 
their understanding about the condition. Improved communication between clinic 
providers and patients can lead to greater client knowledge, which has been 
associated with an increase in colposcopy compliance [32, 33]. Clients should be 
encouraged to ask questions during consultations so that individual concerns can 
be addressed. In addition, client educational materials explaining the importance 
of Pap smears, cervical cancer and the colposcopy procedure in local languages 
understandable to clients are required.
The inadequate provider explanation reported by clients may be related to primary 
care providers’ limited knowledge about the importance of Pap smears and 
management of women with precancerous lesions. This was illustrated previously 
by Moodley et al [7] in a study conducted in three provinces in South Africa. The 
lack of provider knowledge could be related to the limited emphasis allocated to 
cervical screening in the current nursing curriculum, resulting in nurses being ill 
equipped with knowledge and skills required for cervical screening services [34]. 
Psychosocial factors such as fear of cancer as a terminal illness and fear of the 
unknown influenced colposcopy attendance. Women experienced both fear and 
anxiety with the abnormal Pap smear result and the colposcopy procedure. 
Although, the majority of non-attendees had not explicitly reported fear as a 
primary reason for non-attendance, it was a clear concern for many clients. Thus, 
fear may have been a contributing factor to non-attendance. Other studies have 
confirmed that a fear of cancer and fear of the unknown had a negative impact on 
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colposcopy attendance [10, 18, 29, 30]. This illustrates the importance of 
addressing client fears during patient consultations.
Clients were fearful of cancer, particularly due to a family history of cancer and 
the association with death. Our findings are in line with other research – that a 
family history of, and death resulting from, cancer facilitated colposcopy 
attendance [16, 30]. 
Previous studies have reported that women do not attend colposcopy 
appointments due to fear that the procedure would compromise fertility [10, 16, 
29]. This issue was not spontaneously raised by clients in our study. Fertility may 
not have been an issue for women in this study due to the average age of women 
being 40 and all clients had at least one child. 
Transport costs were an important factor influencing colposcopy attendance. 
Many non-attendees were unemployed and were unable to afford the transport 
costs to attend their appointment. Availability of colposcopy services mainly at 
tertiary and secondary hospitals and performed by specialists further restricts 
client access [35]. The impact of transport and distance has been confirmed in 
other studies as a barrier to colposcopy attendance [7, 11, 36]. Proximity to health 
facilities is an important factor in increasing access to health care and for 
improved health outcomes [37]. This provides an important reason for district 
based health care [38].
Other South African studies have found that health system factors including 
inadequate feedback mechanisms and staff shortages have a considerable effect on 
colposcopy attendance [7, 11, 12]. In our study, inadequate feedback mechanisms 
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and staff shortages resulted in clients not being informed of their results thus 
leading to non-attendance at colposcopy. 
A variety of methods were used to inform clients of Pap smear results and 
colposcopy appointments, but there was no co-ordination between methods. A 
few methods included: a colposcopy letter sent via the postal service from the 
cytology laboratory; at times, clients received the letter before being informed 
about their Pap smear results from their clinic provider; a telephone call received 
from a clinic provider or from the colposcopy clinic tracing team; or with a 
combination of methods. The lack of standardisation and co-ordination involved 
in the process of informing clients of Pap smear results and referral to colposcopy 
appointments point towards the fragmentation of services and contributes to 
difficulties in providers monitoring which clients have been informed of results 
and colposcopy appointments. The disjointed system between the laboratory, the 
primary level clinic, and the colposcopy clinic, leads on the one hand to a 
duplication in informing clients of results and colposcopy appointments, and on 
the other hand some clients being missed altogether. This is an inefficient use of 
financial and human resources. A standardised system of colposcopy scheduling 
is needed, with the various role players having clearly defined responsibilities to 
avoid women with abnormal Pap smears from slipping through the system. A 
uniform, electronic-information system which allows providers from the different 
facilities to record which clients have been informed of Pap smear results and 
colposcopy appointments, and which clients have defaulted, is required.  This will 
allow for a coordinated system of monitoring and assist with client tracing.
The introduction of electronic medical records (EMR) may also assist health 
facilities in keeping track of patients who need to return for follow-up procedures 
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and improve efficiency. However, this technology may not be feasible for South 
Africa at present, but should certainly be integrated in the health care system in 
the near future.  
This study had a few limitations. Firstly, some clients were less receptive to 
communicating via the telephone and could have influenced the depth of their 
responses. Secondly, even though clients were conversant in English and 
Afrikaans, neither may have been their first language and could have influenced 
their understanding and ability to fully express their experiences. Thirdly, the 
results from this study are not necessarily generalisable to other contexts as the 
study was conducted predominantly in an urban setting. People living in rural 
areas could have other barriers. However, results from this study can offer 
valuable insight into understanding barriers and facilitators that women with 
abnormal Pap smears may experience.
Recommendations
Interventions to improve knowledge and understanding of Pap smears and 
cervical cancer are needed at various levels.    
1) At the general public level
Mass education programmes to increase community awareness about cervical 
cancer, the purpose and possible outcomes of Pap smear screening, as well as 
emphasise the importance of further evaluation of an abnormal Pap smear. 
Collaborating with traditional healers could assist with increasing community 
awareness and encourage women to attend colposcopy. 
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For women having Pap smears
Education should emphasise that precancerous lesions can be asymptomatic 
and stress the importance of follow-up. Psychosocial factors should also be 
addressed during the Pap smear consultation to reduce client fears. 
At the health system level
Education programmes on Pap smears, cervical cancer and the colposcopy 
procedure are required at health facilities to ensure that clients are adequately 
informed.
A standardised system of informing clients of results and colposcopy 
appointments is essential to ensure clients requiring colposcopy are informed 
of Pap smear results and appointments. A centralised information system is 
required to ensure monitoring of clients attending colposcopy and to decrease 
patient LTFU. 
Additional training should be provided to primary level nurses to ensure that a 
quality service is provided and client concerns addressed.
Colposcopy services should be established closer to the community, for 
example, at primary health care clinics. Training nurses and general 
practitioners to perform colposcopies could make the services more 
accessible.
It would be valuable to fast track clients returning to the clinic for Pap smear 
results to improve efficiency and encourage clients to collect results. The 
implementation of EMR could also decrease waiting times and improve 
efficiency. 
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Client contact details should be updated at each patient visit so that clients are 
able to be reached. 
Better forms of tracing which are cost effective and efficient are required to 
reduce LTFU of clients. Since the majority of patients use mobile phones, 
text messages with short information messages about Pap smears and cervical 
cancer can be used as reminders to collect Pap smear results and to attend 
colposcopy appointments. Text messages have been found to be as effective 
as telephone reminders in increasing adherence to general outpatient 
appointments, and are more cost effective [40]. It would be worthwhile 
testing the effectiveness of text messages as a reminder system for 
colposcopy attendance and as a means of tracing, for future research. 
Conclusions
This study identified multiple barriers influencing attendance at colposcopy. The 
most important barriers included a lack of knowledge of the importance of a Pap 
smear and the colposcopy procedure; a lack of awareness of cervical cancer as a 
disease; being asymptomatic; transport costs; and health system failures including 
the inadequate feedback of Pap smear results and a disjointed system of 
colposcopy scheduling. Addressing these barriers can improve colposcopy 
adherence and ultimately decrease cervical cancer morbidity and mortality.
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1PART D: APPENDICES
2Addendum 1
Interview Guide for Clients
Good morning,
We will be having an interview to discuss why women do and do not attend 
their colposcopy follow-up appointments after having an abnormal Pap 
smear result. We will also be looking at your knowledge and experiences of 
cervical cancer, Pap smears and colposcopy. I reassure you that all 
information discussed will be kept confidential. 
Exploring clients’ knowledge and experiences
Individual factors: 
1.    Could you tell me why you are here today?
2.    How do you feel about today’s appointment?
3.    Could you tell me what the importance is of having a Pap smear?
3.1. Could you tell me what made you have a Pap smear? 
3.2. Could you describe/discuss your experiences thus far since you received your 
abnormal Pap smear result?
4.   Could you tell me what do you know about the procedure or test you coming 
for today?
4.1. Have you had any difficulties or problems in coming for your appointment 
today?
Probe if unable to answer - time off from work? 
-Problems with childcare?
-Transport?
- Or any other?
5. Many women do not attend their follow–up appointment after an abnormal Pap     
test. Why do you think this is so?
(If did not attend): 
5b.    Did you know that you had a colposcopy appointment on (day)?
5b.1  Could you tell me what the reason/s were for not attending?
5b.2. Are you still interested in attending/ making another appointment?
Ask question 3 and 4, then continue 
Intrapersonal factors:  
6.   Have you told anyone about your abnormal smear or that you not feeling 
well? Who?  
3If No, how do you feel about being the only one knowing about your 
abnormal  Pap smear?
6.1. Have you received any help or support from them? In what way have they      
helped or supported you?
If No, would you have liked to receive support from someone? What kind 
of support or help would you have liked to receive?
Institutional/Health system factors:
7.    How did you find out that you needed a colposcopy?
7.1. What did the clinic staff tell you about colposcopy?
7.2. Who explained the result of your Pap smear to you?
7.3. Do you understand what the result means? 
- Can you tell me what it means?
8. Do you have any concerns about the procedure? Or about the medical staff ?
9. Can you tell me, the health services you received at the time of having the Pap 
smear, how can it be improved or made more convenient for you as a patient?
Community/Environmental factors: 
10. How do the people in your community (e.g. friends, family, neighbours, 
leaders) view someone with cervical cancer? 
11. Can you tell me if there are any other treatments that you have used for your                                       
illness before coming to the doctors for help? e.g. herbal or traditional
Probes - What kind of treatment/s have you received?
- How effective was it?
10. Is there anything else you concerned about or you would like to share?
Probes - Anything regarding the Pap smear?
- The colposcopy procedure?
Well, this brings us to the end of our interview.
Thank you very much for sharing your experiences with me, just to reassure you 
that all information shared is strictly confidential.
Good luck with your appointment.
4Addendum 2
Client Information Form
Study: Barriers and facilitators of colposcopy attendance among women 
following an abnormal pap smear in Cape Town.
Participant archival number: Date of interview:
Age:
Address:
Interview language: 
Contact number: (H)                                                          cell:
Nationality:
Marital status: single               married                  divorced           widowed
Employment:
Highest education level:
Children:
Date of Pap smear:
Referring clinic:
Pap smear result:
5Addendum 3
Interview Guide with Head of Colposcopy Clinic 
Good morning, in our interview we will be discussing the effectiveness of the 
new telephonic tracing system implemented at GSH in improving attendance 
rates at colposcopy clinic   and the sustainability thereof for the rest of the 
country. We will also be addressing the use of a sms tracing system and its 
challenges in an attempt to improve attendance rates at colposcopy clinic.
1.) How effective has the new telephonic tracing system that’s been implemented      
at GSH been in improving the attendance rates as well as retaining the women 
that had missed their colposcopy appointments?
b.) Can this system at GSH be used at public health facilities across the country?        
And if so how? 
c.) What will be required/ what will it take for this system to be put into               
operation?
d.) Do you think it will be sustainable?
2.) What are your views about the use of sms’s for colposcopy appointment                
reminders and health information messages?
b.) Do you think it’s a good idea? And Why?
c.) What would be the challenges?
d.) With the sms’s you want clients to be concerned enough to attend, but at the    
same time not paralysed with fear and not attend.                                   
What do you think the sms message to clients should entail (i.e. the content)?
Is there anything else you would like to add or share with me?
This brings us to the end of our interview; I thank you very much for taking the 
time out of your busy schedule for this interview and appreciate you sharing your 
views with me.  Thank you
6Addendum 4
Interview Guide for Health Care Providers at the Colposcopy Clinic
Good morning, we will be having an interview addressing barriers and 
facilitators to colposcopy follow-up by women following an abnormal Pap 
smear result from a provider perspective.
-Reassurance about confidentiality
Individual and community factors:
1. What factors or issues do you think influences woman’s adherence to 
recommended follow- up care following an abnormal Pap smear?
Probes - anything about their personal circumstances or situation?
- Language barriers?
- Anything about getting medical care?
- Anything about the health care providers?
- Cultural influences? Or beliefs?
- Transport?
- Distance?
- Anything regarding scheduling of appointments?
Health system/ Institutional factors:
2. In your opinion, can you describe the significance of non- attendance at 
colposcopy assessment following an abnormal Pap smear?
2.1 Do you think this problem of non-attendance is related to the availability of 
services that is available to women? 
Probes - What services are available?
- What services are not available that ideally should be?
3. Can you describe the communication channels between the colposcopy clinic   
and the referral clinics?
4. What happens to the patients who do not attend colposcopy?
Probe- Is there any way to follow them up? If yes proceed to 4.1.
4.1 How successful has this form of tracing been in retaining women who have     
missed their appointments?
75. How important do you feel it is for patients to attend their follow-up?    
appointments?
6. What problems or challenges are you as a health care provider faced with in the    
provision of Pap smear/colposcopy services to these women?
6.1 How do you think services can be improved in order to improve colposcopy         
attendance rates? 
7. Is there anything else that you would like to share? 
Our interview has come to an end, Thank you for your time and your valuable 
contributions.
8Addendum 5
Interview Guide for Health Care Providers at Clinics
Good morning, we will be having an interview addressing barriers and 
facilitators to colposcopy follow-up by women following an abnormal Pap 
smear result from a provider perspective.
-Reassurance about confidentiality
Individual /intrapersonal factors, community/ environmental factors:
1. 1. What factors or issues do you think influences women’s adherence to 
recommended follow-up care following an abnormal Pap smear?
Probes - anything about their personal circumstances or situation?
- Language barriers?
- Anything about getting medical care?
- Anything about the health care providers
- Cultural influences? Or beliefs?
- Transport?
- Distance?
- Anything regarding scheduling of appointments?
Health system/ Institutional factors:
2. 1 What is the process that follows once women have come to the clinic for 
their Pap smear?
2.2 What is the process involved in informing clients of their Pap smear results?
2.3 If patients do not return for their result, what measures are in place to track      
women in order to inform them of their result?                              
Probe- What about if it is an abnormal result?
3.   Can you tell me how are the colposcopy appointments made for clients?
4. 1 Can you describe the communication channels between your clinic/s and the 
colposcopy clinic?
4.2 Are you informed about patients that do not attend? 
4.3 What is done about the clients that do not attend their colposcopy         
appointment?
5.  How do you feel about the process of appointment making for colposcopy?
6. How important do you think it is for patients to attend their colposcopy follow-
up?
7. Do you think this problem of non-attendance is related to the type of services     
that is available to women?
98.1 What problems or challenges are you as a health care provider faced with in             
the provision of Pap smear services to women?
8.2 How do you think services can be improved in order to improve attendance        
rates at colposcopy?
Is there anything else you would like to add? 
Our interview has come to an end, thank you for your time and I appreciate your 
valuable contribution.
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Addendum 6
Interview Guide for Administration Assistant at Cytology Lab
Good morning, 
We will be having an interview exploring your role in the administration and 
organisation of colposcopy appointments for women who has had an 
abnormal Pap smear. 
Administration Factors:
1. Can you explain to me what your role is at the cytology lab regarding the Pap 
smears and colposcopy follow-up appointments?
2.1 How do you determine who needs to be booked for a colposcopy?
2.2 What process do you follow to ensure that a booking is made?
2.3 Once a booking has been made, how are these women informed of their 
appointment?
Health System Factors:
3. What if women are unable to attend the given appointment date? What happens       
then?
Probes- What options are available to them?
- Are they able to reschedule?  How?
- Are they aware of it? 
- When do they then get another appointment?
4.1 How long do women have to wait before getting an appointment?
4.2 Can you tell me what contributed to the long waiting period? 
5. What challenges are you faced with?
5.1 How do you think these challenges can be improved?
Is there anything else you would like to share?
The interview has come to an end. Thank you for your time and valuable 
feedback. 
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Addendum 7
Data tracking Form for Interviews              Archival Log  
Interviewee 
category 
(attendee/non-
attendee/ HP)
Archival 
Number Age Interviewer Transcriber Typist
Interview 
Date
Interview 
Language
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Addendum 8
Consent to participate in Research: Client Consent Form
Good morning, I am Shanaaz Dawood, a researcher studying at the University of 
Cape Town. We are conducting a study to better understand reasons why women 
do and do not attend their follow-up appointment at the colposcopy clinic after 
having an abnormal Pap smear result.
You are now being requested to volunteer to participate in an interview under the 
guidance of the University of Cape Town. Participating in the study is completely 
voluntary and you are not forced to partake. 
For this study we will need to conduct an Individual interview. During the 
interview I will ask you a few questions about yourself, followed by questions 
with regard to your knowledge of Pap smears, cervical cancer and colposcopy, as 
well as reasons why you think women attend or do not attend their follow-up 
appointment. Other questions will involve your experiences regarding the health 
services received. The interview will be conducted in a private room in which no 
one else except myself will be present. The total interview should take no more 
than about 45 minutes. Interviews will be recorded with your permission.
Your name and all information discussed during the interview with the researcher 
will be kept confidential. Your name will not be used in the research. You will be 
given a number instead so that you are not identified in the research. The 
information you provide the researcher with as well as all recordings will only be 
made available to the main researcher, supervisor and co-supervisor who will 
assist in analysing the information. 
Once again you do not have to take part in the study it is completely voluntary and 
you can withdraw at any stage of the study. If you decide not to partake in the 
study you will still continue receiving all the treatment you have been receiving. If 
you participate you do not have to answer any question that you do not want to.
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Potential Benefits:
The information you provide us with will assist in improving health services in 
the future so that more women at risk of cancer attend their colposcopy follow-up 
appointments. You will be a given a light refreshment for your time. 
Potential Risks and Discomforts:
During the interview process certain questions may cause certain negative feelings 
to arise which may make you feel uncomfortable, if you feel that you do not want 
to answer those questions please tell the researcher. During the interview you may 
feel uncertain or have questions regarding the colposcopy assessment, these can 
be answered by the specialist doctor.
If during the study you feel that you  have been in any way or you have any 
further concerns regarding the study please feel free to contact the main 
researcher, Mrs Shanaaz Dawood on  021 5315477 or  0823581282   or email 
shanaaz59@yahoo.com or  you may contact the UCT Health Science Human 
Research Ethics Committee on 021 4066338. 
If you have any questions or concerns regarding the study you may ask them now 
or later. If you do not have any questions and agree to participate we will go 
ahead with the interview. Before we start I will ask you to sign this form stating 
that I, the interviewer have read and explained to you your rights as a participant 
and you agreed to participate in the discussion.
Participation:
The researcher has read the form to me and I understand the process of the study. 
It has also been explained to me. I am aware that participation is completely 
voluntary and I can withdraw at any time. I had an opportunity to ask questions 
and all questions and concerns have been adequately addressed by the researcher.
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Participant signature.................................. Date.....................
Hospital.......................................................
Researcher Name........................................
Researcher Signature..................................
Telephonic consent
Participant name......................................…..                        Date.....................
Researcher Name...........................................
Researcher Signature.....................................
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Addendum 9
Consent to participate in Research: Health Provider Consent Form
Good Morning, I am a researcher studying at the University of Cape Town. 
We are conducting this study to better understand the reasons why women do and 
do not attend their follow-up appointment at colposcopy clinic after having an 
abnormal Pap smear result. The results of this study will assist in improving 
health services, to ensure that more women with abnormal Pap smear results 
attend their follow-up appointments and receive the appropriate care and 
treatment, in order to decrease the progression to cervical cancer.
You are now being requested to volunteer to participate in an interview under the 
guidance of the University of Cape Town. Participating in the study is completely 
voluntary and you are not forced to partake. 
Individual interviews will be conducted in a private room in which you will be 
asked a few questions with regard to barriers and facilitators to colposcopy 
attendance, from a providers’ point of view. The total interview should take no 
more than about forty minutes. Interviews will be recorded with your permission.
Your name and all information discussed and disclosed during the interview with 
the researcher will be kept confidential. Your name will not be used in the 
research. You will be given a number to ensure anonymity. The information you 
provide the researcher with as well as all recordings will only be made available 
to the main researcher, supervisor and co-supervisor who will assist in analysing 
the information. 
Once again you do not have to take part in the study it is completely voluntary and 
you can withdraw at any stage of the study. If you participate you do not have to 
answer any question that you do not want to.
Potential Benefits:
The information you provide us with will assist in improving health services in 
the future so that more women at risk of cancer attend their colposcopy follow-up 
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appointments. Once the research is complete you will be contacted and provided 
with the results of the study.
Potential Risks and Discomforts:
There are no foreseeable risks for participating. During the interview process, you 
may feel some discomfort in answering any question, if you feel that you do not 
want to answer those questions please tell the researcher. 
If  you feel that during the study you have been harmed in any way or if you have 
any further concerns regarding the study please feel free to contact the principal 
researcher, Mrs Shanaaz Dawood on 021 5315477 or cell  0823581282   or email 
shanaaz59@yahoo.com or you may contact the UCT Health Science Human 
Research Ethics Committee on 021 4066338.
If you have any questions or concerns regarding the study you may ask them now 
or later. If you do not have any questions and agree to participate we will go 
ahead with the interview. Before we start I will ask you to sign this form stating 
that I, the interviewer have explained to you your rights as a participant and you 
agreed to participate in the discussion.
Participation:
I have read the letter and understand the process of the study. It has also been 
explained to me. I am aware that participation is completely voluntary and I can 
withdraw at any time. I had an opportunity to ask questions and all questions and 
concerns have been adequately addressed by the researcher.
Health Provider Signature................................ Date.....................
Hospital..............................................
Researcher Name.........................................
Researcher Signature..................................
Addendum 10 Ethics Approval Letter
17
Addendum 11                   Annual Ethics Progress Report
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Addendum 12
Instructions for authors BMC Public Health
Research articles
Criteria | Submission process | Preparing main manuscript text | Preparing 
illustrations and figures |Preparing tables | Preparing additional files | Style and 
language
Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team. See 'About this journal' for 
information about policies and the refereeing process. We also provide a 
collection of links to useful tools and resources for scientific authors on our page.
Criteria
Research articles should report on original primary research, but may report on 
systematic reviews of published research provided they adhere to the appropriate 
reporting guidelines which are detailed in our Editorial Policies. Please note that 
non-commissioned pooled analyses of selected published research will not be 
considered.
Submission process
Manuscripts must be submitted by one of the authors of the manuscript, and 
should not be submitted by anyone on their behalf. The submitting author takes 
responsibility for the article during submission and peer review.
Please note that BMC Public Health levies an article-processing charge on all 
accepted Research articles; if the submitting author's institution is a BioMed 
Central member the cost of the article-processing charge may be covered by the 
membership (see About page for detail). Please note that the membership is only 
automatically recognised on submission if the submitting author is based at the 
member institution.
To facilitate rapid publication and to minimize administrative costs, BMC Public 
Health prefers online submission.
Files can be submitted as a batch, or one by one. The submission process can be 
interrupted at any time; when users return to the site, they can carry on where they 
left off.
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See below for examples of word processor and graphics file formats that can be 
accepted for the main manuscript document by the online submission system. 
Additional files of any type, such as movies, animations, or original data files, can 
also be submitted as part of the manuscript.
During submission you will be asked to provide a cover letter. Use this to explain 
why your manuscript should be published in the journal, to elaborate on any 
issues relating to our editorial policies in the 'About BMC Public Health' page, 
and to declare any potential competing interests. You will be also asked to provide 
the contact details (including email addresses) of potential peer reviewers for your 
manuscript. These should be experts in their field, who will be able to provide an 
objective assessment of the manuscript. Any suggested peer reviewers should not 
have published with any of the authors of the manuscript within the past five 
years, should not be current collaborators, and should not be members of the same 
research institution. Suggested reviewers will be considered alongside potential 
reviewers recommended by the Editorial team, Editorial Advisors, Section Editors 
and Associate Editors.
Assistance with the process of manuscript preparation and submission is available 
from BioMed Central customer support team.
We also provide a collection of links to useful tools and resources for scientific 
authors on our Useful Tools page.
Preparing main manuscript text
General guidelines of the journal's style and language are given below.
Overview of manuscript sections for Research articles
Manuscripts for Research articles submitted to BMC Public Health should be 
divided into the following sections (in this order):
 Title page
 Abstract
 Keywords
 Background
 Methods
 Results and discussion
 Conclusions
 List of abbreviations used (if any)
 Competing interests
 Authors' contributions
 Authors' information
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 Acknowledgements
 Endnotes
 References
 Illustrations and figures (if any)
 Tables and captions
 Preparing additional files
You can download a template (Mac and Windows compatible; Microsoft Word 
98/2000) for your article.
For reporting standards please see the information in the About section.
Title page
The title page should:
 provide the title of the article
 list the full names, institutional addresses and email addresses for all    
authors
 indicate the corresponding author
Please note:
 The title should include the study design, for example "A versus B in 
the treatment of C: a randomized controlled trial X is a risk factor for Y: 
a case control study"
 abbreviations within the title should be avoided
Abstract
The Abstract of the manuscript should not exceed 350 words and must be 
structured into separate sections: Background, the context and purpose of the 
study;Methods, how the study was performed and statistical tests used; Results, 
the main findings; Conclusions, brief summary and potential implications. Please 
minimize the use of abbreviations and do not cite references in the abstract. Trial 
registration, if your research article reports the results of a controlled health care 
intervention, please list your trial registry, along with the unique identifying 
number (e.g. Trial registration: Current Controlled Trials ISRCTN73824458). 
Please note that there should be no space between the letters and numbers of your 
trial registration number. We recommend manuscripts that report randomized 
controlled trials follow the CONSORT extension for abstracts.
Keywords
Three to ten keywords representing the main content of the article.
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Background
The Background section should be written in a way that is accessible to 
researchers without specialist knowledge in that area and must clearly state - and, 
if helpful, illustrate - the background to the research and its aims. Reports of 
clinical research should, where appropriate, include a summary of a search of the 
literature to indicate why this study was necessary and what it aimed to contribute 
to the field. The section should end with a brief statement of what is being 
reported in the article.
Methods
The methods section should include the design of the study, the setting, the type 
of participants or materials involved, a clear description of all interventions and 
comparisons, and the type of analysis used, including a power calculation if 
appropriate. Generic drug names should generally be used. When proprietary 
brands are used in research, include the brand names in parentheses in the 
Methods section.
For studies involving human participants a statement detailing ethical approval 
and consent should be included in the methods section. For further details of the 
journal's editorial policies and ethical guidelines see 'About this journal'.
For further details of the journal's data-release policy, see the policy section 
in 'About this journal'.
Results and discussion
The Results and discussion may be combined into a single section or presented 
separately. Results of statistical analysis should include, where appropriate, 
relative and absolute risks or risk reductions, and confidence intervals. The 
Results and discussion sections may also be broken into subsections with short, 
informative headings.
Conclusions
This should state clearly the main conclusions of the research and give a clear 
explanation of their importance and relevance. Summary illustrations may be 
included.
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List of abbreviations
If abbreviations are used in the text they should be defined in the text at first use, 
and a list of abbreviations can be provided, which should precede the competing 
interests and authors' contributions.
Competing interests
A competing interest exists when your interpretation of data or presentation of 
information may be influenced by your personal or financial relationship with 
other people or organizations. Authors must disclose any financial competing 
interests; they should also reveal any non-financial competing interests that may 
cause them embarrassment were they to become public after the publication of the 
manuscript.
Authors are required to complete a declaration of competing interests. All 
competing interests that are declared will be listed at the end of published articles. 
Where an author gives no competing interests, the listing will read 'The author(s) 
declare that they have no competing interests'.
When completing your declaration, please consider the following questions:
Financial competing interests
 In the past five years have you received reimbursements, fees, funding, or 
salary from an organization that may in any way gain or lose financially from 
the publication of this manuscript, either now or in the future? Is such an 
organization financing this manuscript (including the article-processing 
charge)? If so, please specify.
 Do you hold any stocks or shares in an organization that may in any way 
gain or lose financially from the publication of this manuscript, either now or 
in the future? If so, please specify.
 Do you hold or are you currently applying for any patents relating to the 
content of the manuscript? Have you received reimbursements, fees, funding, 
or salary from an organization that holds or has applied for patents relating to 
the content of the manuscript? If so, please specify.
 Do you have any other financial competing interests? If so, please specify.
Non-financial competing interests
Are there any non-financial competing interests (political, personal, religious, 
ideological, academic, intellectual, commercial or any other) to declare in relation 
to this manuscript? If so, please specify.
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If you are unsure as to whether you, or one your co-authors, has a competing 
interest please discuss it with the editorial office.
Authors' contributions
In order to give appropriate credit to each author of a paper, the individual 
contributions of authors to the manuscript should be specified in this section.
According to ICMJE guidelines, An 'author' is generally considered to be 
someone who has made substantive intellectual contributions to a published study. 
To qualify as an author one should 1) have made substantial contributions to 
conception and design, or acquisition of data, or analysis and interpretation of 
data; 2) have been involved in drafting the manuscript or revising it critically for 
important intellectual content; 3) have given final approval of the version to be 
published; and 4) agree to be accountable for all aspects of the work in ensuring 
that questions related to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved. Each author should have participated 
sufficiently in the work to take public responsibility for appropriate portions of the 
content. Acquisition of funding, collection of data, or general supervision of the 
research group, alone, does not justify authorship.
We suggest the following kind of format (please use initials to refer to each 
author's contribution): AB carried out the molecular genetic studies, participated 
in the sequence alignment and drafted the manuscript. JY carried out the 
immunoassays. MT participated in the sequence alignment. ES participated in the 
design of the study and performed the statistical analysis. FG conceived of the 
study, and participated in its design and coordination and helped to draft the 
manuscript. All authors read and approved the final manuscript.
All contributors who do not meet the criteria for authorship should be listed in an 
acknowledgements section. Examples of those who might be acknowledged 
include a person who provided purely technical help, writing assistance, or a 
department chair who provided only general support.
Authors' information
You may choose to use this section to include any relevant information about the 
author(s) that may aid the reader's interpretation of the article, and understand the 
standpoint of the author(s). This may include details about the authors' 
qualifications, current positions they hold at institutions or societies, or any other 
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relevant background information. Please refer to authors using their initials. Note 
this section should not be used to describe any competing interests.
Acknowledgements
Please acknowledge anyone who contributed towards the article by making 
substantial contributions to conception, design, acquisition of data, or analysis and 
interpretation of data, or who was involved in drafting the manuscript or revising 
it critically for important intellectual content, but who does not meet the criteria 
for authorship. Please also include the source(s) of funding for each author, and 
for the manuscript preparation. Authors must describe the role of the funding 
body, if any, in design, in the collection, analysis, and interpretation of data; in the 
writing of the manuscript; and in the decision to submit the manuscript for 
publication. Please also acknowledge anyone who contributed materials essential 
for the study. If a language editor has made significant revision of the manuscript, 
we recommend that you acknowledge the editor by name, where possible.
The role of a scientific (medical) writer must be included in the 
acknowledgements section, including their source(s) of funding. We suggest 
wording such as 'We thank Jane Doe who provided medical writing services on 
behalf of XYZ Pharmaceuticals Ltd.'
Authors should obtain permission to acknowledge from all those mentioned in the 
Acknowledgements section.
Endnotes
Endnotes should be designated within the text using a superscript lowercase letter 
and all notes (along with their corresponding letter) should be included in the 
Endnotes section. Please format this section in a paragraph rather than a list.
References
All references, including URLs, must be numbered consecutively, in square 
brackets, in the order in which they are cited in the text, followed by any in tables 
or legends. Each reference must have an individual reference number. Please 
avoid excessive referencing. If automatic numbering systems are used, the 
reference numbers must be finalized and the bibliography must be fully formatted 
before submission.
Only articles, datasets, clinical trial registration records and abstracts that have 
been published or are in press, or are available through public e-print/preprint 
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servers, may be cited; unpublished abstracts, unpublished data and personal 
communications should not be included in the reference list, but may be included 
in the text and referred to as "unpublished observations" or "personal
communications" giving the names of the involved researchers. Obtaining 
permission to quote personal communications and unpublished data from the cited 
colleagues is the responsibility of the author. Footnotes are not allowed, but 
endnotes are permitted. Journal abbreviations follow Index Medicus/MEDLINE. 
Citations in the reference list should include all named authors, up to the first 30 
before adding 'et al.'..
Any in press articles cited within the references and necessary for the reviewers' 
assessment of the manuscript should be made available if requested by the 
editorial office.
Style files are available for use with popular bibliographic management software:
 BibTeX
 EndNote style file
 Reference Manager
 Zotero
Examples of the BMC Public Health reference style are shown below. Please 
ensure that the reference style is followed precisely; if the references are not in the 
correct style they may have to be retyped and carefully proofread.
All web links and URLs, including links to the authors' own websites, should be 
given a reference number and included in the reference list rather than within the 
text of the manuscript. They should be provided in full, including both the title of 
the site and the URL, in the following format: The Mouse Tumor Biology 
Database [http://tumor.informatics.jax.org/mtbwi/index.do]. If an 
author or group of authors can clearly be associated with a web 
link, such as for weblogs, then they should be included in the 
reference.
Examples of the BMC Public Health reference style
Article within a journal
Koonin EV, Altschul SF, Bork P: BRCA1 protein products: functional 
motifs. Nat Genet 1996,13:266-267.
Article within a journal supplement
Orengo CA, Bray JE, Hubbard T, LoConte L, Sillitoe I: Analysis and 
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assessment of ab initio three-dimensional prediction, secondary structure, 
and contacts prediction. Proteins 1999,43(Suppl 3):149-170.
In press article
Kharitonov SA, Barnes PJ: Clinical aspects of exhaled nitric oxide. Eur 
Respir J, in press.
Published abstract
Zvaifler NJ, Burger JA, Marinova-Mutafchieva L, Taylor P, Maini 
RN: Mesenchymal cells, stromal derived factor-1 and rheumatoid arthritis 
[abstract]. Arthritis Rheum 1999, 42:s250.
Article within conference proceedings
Jones X: Zeolites and synthetic mechanisms. In Proceedings of the First 
National Conference on Porous Sieves: 27-30 June 1996; Baltimore. Edited by 
Smith Y. Stoneham: Butterworth-Heinemann; 1996:16-27.
Book chapter, or article within a book
Schnepf E: From prey via endosymbiont to plastids: comparative studies in 
dinoflagellates. In Origins of Plastids. Volume 2. 2nd edition. Edited by 
Lewin RA. New York: Chapman and Hall; 1993:53-76.
Whole issue of journal
Ponder B, Johnston S, Chodosh L (Eds): Innovative 
oncology. In Breast Cancer Res 1998, 10:1-72.
Whole conference proceedings
Smith Y (Ed): Proceedings of the First National Conference on Porous Sieves: 
27-30 June 1996; Baltimore. Stoneham: Butterworth-Heinemann; 
1996.
Complete book
Margulis L: Origin of Eukaryotic Cells. New Haven: Yale University 
Press; 1970.
Monograph or book in a series
Hunninghake GW, Gadek JE: The alveolar macrophage. In Cultured 
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Human Cells and Tissues.Edited by Harris TJR. New York: Academic 
Press; 1995:54-56. [Stoner G (Series Editor): Methods and 
Perspectives in Cell Biology, vol 1.
Book with institutional author
Advisory Committee on Genetic Modification: Annual 
Report. London; 1999.
PhD thesis
Kohavi R: Wrappers for performance enhancement and oblivious decision 
graphs. PhD thesis. Stanford University, Computer Science 
Department; 1995.
Link / URL
The Mouse Tumor Biology 
Database [http://tumor.informatics.jax.org/mtbwi/index.do]
Link / URL with author(s)
Corpas M: The Crowdfunding Genome Project: a personal genomics 
community with open source values
[http://blogs.biomedcentral.com/bmcblog/2012/07/16/the-
crowdfunding-genome-project-a-personal-genomics-community-
with-open-source-values/]
Dataset with persistent identifier
Zheng, L-Y; Guo, X-S; He, B; Sun, L-J; Peng, Y; Dong, S-S; Liu, 
T-F; Jiang, S; Ramachandran, S; Liu, C-M; Jing, H-C 
(2011): Genome data from sweet and grain sorghum (Sorghum 
bicolor).GigaScience. http://dx.doi.org/10.5524/100012.
Clinical trial registration record with persistent identifier
Mendelow, AD (2006): Surgical Trial in Lobar Intracerebral 
Haemorrhage. Current Controlled 
Trials. http://dx.doi.org/10.1186/ISRCTN22153967
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Preparing illustrations and figures
Illustrations should be provided as separate files, not embedded 
in the text file. Each figure should include a single illustration and 
should fit on a single page in portrait format. If a figure consists 
of separate parts, it is important that a single composite 
illustration file be submitted which contains all parts of the 
figure. There is no charge for the use of color figures.
Please read our figure preparation guidelines for detailed instructions 
on maximising the quality of your figures.
Formats
The following file formats can be accepted:
 PDF (preferred format for diagrams)
 DOCX/DOC (single page only)
 PPTX/PPT (single slide only)
 EPS
 PNG (preferred format for photos or images)
 TIFF
 JPEG
 BMP
Figure legends
The legends should be included in the main manuscript text file 
at the end of the document, rather than being a part of the 
figure file. For each figure, the following information should be 
provided: Figure number (in sequence, using Arabic numerals -
i.e. Figure 1, 2, 3 etc); short title of figure (maximum 15 words); 
detailed legend, up to 300 words.
Please note that it is the responsibility of the author(s) to obtain permission 
from the copyright holder to reproduce figures or tables that have previously 
been published elsewhere.
Preparing tables
Each table should be numbered and cited in sequence using 
Arabic numerals (i.e. Table 1, 2, 3 etc.). Tables should also have 
a title (above the table) that summarizes the whole table; it 
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should be no longer than 15 words. Detailed legends may then 
follow, but they should be concise. Tables should always be cited 
in text in consecutive numerical order.
Smaller tables considered to be integral to the manuscript can be 
pasted into the end of the document text file, in A4 portrait or 
landscape format. These will be typeset and displayed in the final 
published form of the article. Such tables should be formatted 
using the 'Table object' in a word processing program to ensure 
that columns of data are kept aligned when the file is sent 
electronically for review; this will not always be the case if 
columns are generated by simply using tabs to separate text. 
Columns and rows of data should be made visibly distinct by 
ensuring that the borders of each cell display as black lines. 
Commas should not be used to indicate numerical values. Color 
and shading may not be used; parts of the table can be 
highlighted using symbols or bold text, the meaning of which 
should be explained in a table legend. Tables should not be 
embedded as figures or spread sheet files.
Larger datasets or tables too wide for a portrait page can be 
uploaded separately as additional files. Additional files will not be 
displayed in the final, laid-out PDF of the article, but a link will be 
provided to the files as supplied by the author.
Tabular data provided as additional files can be uploaded as an 
Excel spread sheet (.xls ) or comma separated values (.csv). As 
with all files, please use the standard file extensions.
Preparing additional files
Although BMC Public Health does not restrict the length and 
quantity of data included in an article, we encourage authors to 
provide datasets, tables, movies, or other information as 
additional files.
Please note: All Additional files will be published along with the 
article. Do not include files such as patient consent forms, 
certificates of language editing, or revised versions of the main 
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manuscript document with tracked changes. Such files should be
sent by email to editorial@biomedcentral.com, quoting the Manuscript 
ID number.
Results that would otherwise be indicated as "data not shown" 
can and should be included as additional files. Since many 
weblinks and URLs rapidly become broken, BMC Public 
Health requires that supporting data are included as additional 
files, or deposited in a recognized repository. Please do not link 
to data on a personal/departmental website. The maximum file 
size for additional files is 20 MB each, and files will be virus-
scanned on submission.
Additional files can be in any format, and will be downloadable 
from the final published article as supplied by the author. We 
recommend CSV rather than PDF for tabular data.
Certain supported files formats are recognized and can be 
displayed to the user in the browser. These include most movie 
formats (for users with the Quicktime plugin), mini-websites 
prepared according to our guidelines, chemical structure files 
(MOL, PDB), geographic data files (KML).
If additional material is provided, please list the following 
information in a separate section of the manuscript text:
 File name (e.g. Additional file 1)
 File format including the correct file extension for example .pdf, .xls, .txt, 
.pptx (including name and a URL of an appropriate viewer if format is 
unusual)
 Title of data
 Description of data
Additional files should be named "Additional file 1" and so on and 
should be referenced explicitly by file name within the body of 
the article, e.g. 'An additional movie file shows this in more 
detail [see Additional file 1]'.
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Additional file formats
Ideally, file formats for additional files should not be platform-
specific, and should be viewable using free or widely available 
tools. The following are examples of suitable formats.
 Additional documentation
o PDF (Adobe Acrobat)
 Animations
o SWF (Shockwave Flash)
 Movies
o MP4 (MPEG 4)
o MOV (Quicktime)
 Tabular data
o XLS, XLSX (Excel Spread sheet)
o CSV (Comma separated values)
As with figure files, files should be given the standard file 
extensions.
Style and language
General
Currently, BMC Public Health can only accept manuscripts written 
in English. Spelling should be US English or British English, but 
not a mixture.
There is no explicit limit on the length of articles submitted, but 
authors are encouraged to be concise.
BMC Public Health will not edit submitted manuscripts for style or 
language; reviewers may advise rejection of a manuscript if it is 
compromised by grammatical errors. Authors are advised to 
write clearly and simply, and to have their article checked by 
colleagues before submission. In-house copyediting will be 
minimal. Non-native speakers of English may choose to make 
use of a copyediting service.
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Abbreviations
Abbreviations should be used as sparingly as possible. They 
should be defined when first used and a list of abbreviations can 
be provided following the main manuscript text.
Typography
 Please use double line spacing.
 Type the text unjustified, without hyphenating words at line breaks.
 Use hard returns only to end headings and paragraphs, not to rearrange     
lines.
 Capitalize only the first word, and proper nouns, in the title.
 All pages should be numbered.
 Use the BMC Public Health reference format.
 Size font 12
 Font style New Times Roman is recommended
 Bold section headings
 Footnotes are not allowed, but endnotes are permitted.
 Please do not format the text in multiple columns.
 Greek and other special characters may be included. If you are unable to  
reproduce a particular special character, please type out the name of the 
symbol in full. Please ensure that all special characters used are 
embedded in the text, otherwise they will be lost during conversion 
to PDF.
Units
SI units should be used throughout (liter and molar are 
permitted, however).
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